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Delineating The Immunometabolism Of Human Invariant Natural Killer T Cells
Abstract
Invariant natural killer T (iNKT) cells comprise a unique subset of T lymphocytes that possess innate-like
functional features and are primed for activation. iNKT cells exert robust anti-tumor cytotoxicity through
both direct mechanisms and by modulation of other immune populations. However, the use of these cells
for immunotherapies has been quite limited, remaining in early clinical stages. This is largely due to our
limited understanding of basic cellular properties of iNKT cells that may influence their ability to survive
and maintain effector functions within the harsh, nutrient-poor solid tumor microenvironment (TME). In
conventional T cells (TCONV), naïve, effector, and memory differentiation states are characterized by
unique metabolic properties and bioenergetic demands that support their dynamic functions. In TCONV,
cellular metabolism is tightly linked to effector functions and their ability to adapt to the nutrient-poor
TME. In contrast, the bioenergetic requirements of iNKT cells – particularly those of human iNKT cells –
at baseline and upon stimulation are not well understood; neither is how these requirements affect
cytokine production or anti-tumor effector functions. Thus, the focus of this thesis work was to
characterize the immunometabolism of iNKT cells and investigated whether this differs from TCONV.
Using transcriptional profiling, nutrient depletion studies, flow-based metabolic dyes, and Seahorse flux
metabolic assays to measure real-time activity, we discover novel immunometabolic features of human
iNKT cells. Unlike TCONV, human iNKT cells were not dependent upon glucose or glutamine for cytokine
production and cytotoxicity upon stimulation. We also found that stimulated human iNKT cells appeared
to be less glycolytic than TCONV and predominantly utilize fatty acid oxidation (FAO). Notably, this
memory-like metabolism of iNKT cells may predict better adaptability to the TME long-term. Future
studies are needed to further probe the immunometabolic features of different phenotypic and functional
subsets of iNKT cells, as well as intratumoral iNKT cells. Importantly, our findings suggest that iNKT cellbased immunotherapeutic strategies could co-opt these unique features of iNKT cells to improve their
efficacy and longevity of anti-tumor responses, a critical need for the field of cancer immunotherapy.
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ABSTRACT
DELINEATING THE IMMUNOMETABOLISM OF HUMAN INVARIANT NATURAL
KILLER T CELLS
Priya Khurana
Hamid Bassiri

Invariant natural killer T (iNKT) cells comprise a unique subset of T lymphocytes that
possess innate-like functional features and are primed for activation. iNKT cells exert
robust anti-tumor cytotoxicity through both direct mechanisms and by modulation of
other immune populations. However, the use of these cells for immunotherapies has
been quite limited, remaining in early clinical stages. This is largely due to our limited
understanding of basic cellular properties of iNKT cells that may influence their ability to
survive and maintain effector functions within the harsh, nutrient-poor solid tumor
microenvironment (TME). In conventional T cells (TCONV), naïve, effector, and memory
differentiation states are characterized by unique metabolic properties and bioenergetic
demands that support their dynamic functions. In TCONV, cellular metabolism is tightly
linked to effector functions and their ability to adapt to the nutrient-poor TME. In contrast,
the bioenergetic requirements of iNKT cells – particularly those of human iNKT cells – at
baseline and upon stimulation are not well understood; neither is how these
requirements affect cytokine production or anti-tumor effector functions. Thus, the focus
of this thesis work was to characterize the immunometabolism of iNKT cells and
investigated whether this differs from TCONV. Using transcriptional profiling, nutrient
depletion studies, flow-based metabolic dyes, and Seahorse flux metabolic assays to
measure real-time activity, we discover novel immunometabolic features of human iNKT
vii

cells. Unlike TCONV, human iNKT cells were not dependent upon glucose or glutamine for
cytokine production and cytotoxicity upon stimulation. We also found that stimulated
human iNKT cells appeared to be less glycolytic than TCONV and predominantly utilize
fatty acid oxidation (FAO). Notably, this memory-like metabolism of iNKT cells may
predict better adaptability to the TME long-term. Future studies are needed to further
probe the immunometabolic features of different phenotypic and functional subsets of
iNKT cells, as well as intratumoral iNKT cells. Importantly, our findings suggest that iNKT
cell-based immunotherapeutic strategies could co-opt these unique features of iNKT
cells to improve their efficacy and longevity of anti-tumor responses, a critical need for
the field of cancer immunotherapy.
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CHAPTER 1: THE BIOLOGY AND ANTI-TUMOR PROPERTIES OF NATURAL
KILLER T (NKT) CELLS

1.1. Overview of innate and adaptive immunity
The immune system represents a complex network of cells and secreted molecules
that provide multiple lines of defense to protect hosts from foreign pathogens and
tumors. The immune system can be divided into two broad classes of responses:
“innate” immunity and “adaptive” immunity. The innate immune system is the first line of
defense, recognizing foreign pathogens through genetically-encoded, innate receptors
and producing a very rapid response. The innate immune system classically is nonspecific, in that the cytokine responses and recruitment of immune cells to the site of
infection or a tumor is not dependent upon antigens presented by these foreign cells.
Some innate immune cell types include macrophages, neutrophils, dendritic cells, and
natural killer (NK) cells, which each have extensive crosstalk between one another and
with adaptive immune cells as well. NK cells are a class of innate lymphoid cells with
professional killing ability, inducing cytotoxicity of target cells in a non-specific manner
and secreting robust levels of pro-inflammatory cytokines. NK cells express a number of
activating and inhibitory receptors, and the balance of signals from these inputs governs
the activation of these cells. NK cells have critical roles in responses to pathogens as
well as against tumor cells.
Adaptive immunity, on the other hand, is characterized by antigen-specific
responses that help distinguish “self” from “non-self.” The two major cell types of the
adaptive immune system include B and T lymphocytes. T cells derive from the
hematopoietic lineage and develop in the thymus, where through somatic recombination,
they express receptors (TCRs) that bind specific peptide antigens presented by
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polymorphic major histocompatibility (MHC) molecules. T cells comprise a very broad
subset of cells with different properties, including CD4+ helper T cells that secrete
different classes of both pro-and anti-inflammatory cytokines, as well as cytotoxic CD8+
T cells. In addition to these conventional αβ T cells, there are other rarer subsets of T
cells with unique TCRs that recognize alternate antigens and developmentally diverge
within the thymus. One example is natural killer T (NKT) cells, a non-conventional subset
of T cells that possess specificity for glycolipid antigens presented by an MHC-like
molecule, CD1d. These cells are the focus of this chapter and this thesis work.
Although the classification of most immune cells is often simplified as either “innate”
or “adaptive”, in reality, the immune system is quite complex – not only is there extensive
crosstalk between innate and adaptive cells and responses, but also, many innate cells
including NK cells display conventionally adaptive immune properties, and some
adaptive immune cells have innate-like features. NKT cells represent an example of this
notion, as they constitute adaptive T cells with unique, innate NK-like effector properties
that bridge innate and adaptive immune responses. A more extensive discussion of NKT
cells is addressed in the sections below and throughout this dissertation.

1.2. NKT cell classification, development, and maturation
Natural killer T (NKT) cells constitute a rare subset of αβ T cells that broadly
possess NK-like characteristics. These cells were first identified in 1987, when three
independent research groups described a subset of αβ-TCR T cells in mice that had
intermediate levels of TCR expression, high frequency of expression of the Vβ8 chain,
and were both CD4- and CD8- (double negative; DN) in phenotype (Budd et al., 1987;
Fowlkes, 1987; (Ceredig et al., 1987). It was next discovered that this subset produced
very high levels of immunoregulatory cytokines, including IL-4, IFN-g, and TNF-α
2

(Yoshimoto; (Arase et al., 1993; Zlotnik et al., 1992). Other groups had also identified
subsets of TCR+ αβ T cells that expressed NK1.1 and were biased towards Vβ8.2
expression, secreted high levels of cytokines, and were either CD4+ or DN (Levitsky et
al., 1991; Sykes, 1990). These early studies collectively were the first to discover this
same unique subset of cells, which in subsequent studies were found to possess key
features that are hallmark characteristics of what are now termed “NKT” cells (Godfrey et
al., 2004).
NKT cells possess a TCR that confers specificity for the monomorphic, MHC Ilike molecule CD1d, which presents glycolipid antigens (Bendelac et al., 1994). During
the CD4+CD8+ double-positive (DP) stage of thymic development, the unique somatic
rearrangement of V, D, and J segments provides NKT cells with a limited TCR repertoire
that confers CD1d specificity; CD1d is expressed by hematopoietic cells including
dendritic cells (DCs), macrophages, and B cells (Bendelac et al., 2007a). NKT cells can
be classified as either type I (invariant), or type II (diverse) NKT cells. The latter subset
of NKT cells are not very well-studied, as their TCR repertoire is more diverse and they
recognize a broader range of lipid antigens (Godfrey et al., 2010). One of these lipid
antigens includes sulfatide, and there is some evidence that these cells may also
recognize self-ligands and microbial antigens as well; however, because these are not
well-characterized, the functional properties of these type II CD1d-restricted NKT cells
are ultimately not fully understood (Singh et al., 2018).
In contrast, type I, invariant natural killer T (iNKT) cells comprise the canonical,
best-characterized NKT cell population and thus will be the focus of this chapter and
dissertation as a whole. iNKT cells possess restricted α and β chains; specifically, Vα14
(mice) or Vα24 (humans) is rearranged to the Jα18 gene segment, and these α chains
are co-expressed to a limited repertoire of β chains, namely Vβ8.2, Vβ2, and Vβ7 in
3

mice or Vβ11 in humans (Godfrey et al., 2004). iNKT cells recognize several identified
synthetic and naturally occurring glycolipid antigens, the most well-known being αgalactosylceramide (α-GalCer), a marine sponge-derived antigen that serves as a potent
stimulatory factor for these cells (Kawano et al., 1997). iNKT cells also recognize
additional microbial α-glucuronylceramides as well as the self-antigen
isoglobotrihexosylceramide (iGb3) (Schümann et al., 2006; Xia et al., 2006).
During the DP stage of thymic development in which TCR recombination occurs,
conventional αβ thymocytes are positively and negatively selected for by thymic
epithelial cells that present peptide antigens presented by MHC I and II molecules. In
contrast, iNKT cells are positively selected through interactions with glycolipid antigenCD1d-expressing cortical thymocytes. CD1d expression by these thymocytes is critical
for iNKT cell development, as CD1d-/- mice do not develop iNKT cells (Godfrey et al.,
2010). The distinct differentiation into iNKT cells is dependent upon signaling from the
Signaling Lymphocyte Activation Molecule (SLAM) family of surface receptors, many of
which signal through the SLAM adaptor protein, SAP. This signal then converges on a
phosphorylation cascade comprised of the tyrosine kinases Fyn and Lck that is required
for iNKT cell differentiation (Chan et al., 2003; Latour et al., 2003). After positive
selection, iNKT cells undergo an orchestrated maturation period, whereby they acquire
activated effector-memory, NK-like features. In a sequential manner, NKT cells acquire
the activation markers CD44 and NK1.1, beginning at stage 0 (CD24hi CD44lo NK1.1-),
followed by stage 1 (CD24lo CD44lo NK1.1-), then stage 2 (CD24lo CD44hi NK1.1-), and
finally, stage 3 (CD24lo CD44hi NK1.1+) (Benlagha, 2002; Benlagha et al., 2005). As they
progress through these maturation stages, iNKT cells acquire NK cell receptors including
NKG2D and members of the Ly49 receptor family; additionally, they acquire functional
markers, including CD69, perforin, and granzymes (Matsuda et al., 2006). Throughout
4

these stages, iNKT cells also shift from predominantly producing high levels of IL-4 and
IL-10 cytokines in stages 1 and 2 to producing abundant levels of IFN-g by stage 3
(Benlagha et al., 2005; Coquet et al., 2008). The early development of NKT cells and
acquisition of this effector-memory-like phenotype is tightly regulated by several
transcription factors, including the bric-a-brac zinc finger transcription factor PLZF. PLZF
is a critical regulator of non-conventional innate-like T lymphocytes, expressed highly in
stage 0 and 1 NKT cells but not in conventional T cells (Kovalovsky et al., 2008; Savage
et al., 2008). Notably, PLZF-deficiency results in reduced iNKT cell expansion,
maturation, and cytokine production, conferring a more naïve phenotype (Mao et al.,
2016), while ectopic expression of PLZF in CD4+ T cells induces NKT-like phenotypic
and functional features (Kovalovsky et al., 2010).
High-resolution comparative transcriptional analysis conducted as a part of the
Immunological Genome (ImmGen) Project confirmed shared properties of iNKT cells
with NK cells and T cells, yet also identified gene expression programs unique to iNKT
cells (Cohen et al., 2013). Firstly, they comprehensively determined that NKT cells
selectively upregulate expression of transcripts encoding several activating and
inhibitory natural killer receptors (NKRs) similar to levels in splenic NK cells over the
course of maturation to stage 3, and indeed, peripheral iNKT cells expressed these
NKRs significantly higher than conventional MHC-restricted αβ T cells. In addition to
NKR expression, iNKT cells also shared a transcriptional profile in additional pathways
with NK cells, including cytokine and chemokine-mediated immunity, signal transduction,
and cell motility. iNKT-cell specific transcription distinct from NK cells and conventional T
cells was mainly composed of pathways such as proliferation and apoptosis (Cohen et
al., 2013). Notably, the effector-memory-like mature functional profile of iNKT cells
shared by NK cells was also acquired by effector CD8+ T cells upon TCR activation,
5

further supporting the notion on a transcriptional level that iNKT cells exit the thymus in a
mature, memory-like, “poised effector” state without any additional activation,
representing a distinct functional difference from conventional T cells.
Overall, the frequencies of iNKT cells in peripheral organs is relatively low. In
mice, the frequencies of iNKT cells in the spleen, blood, and bone marrow range from
0.5-2%, while in the liver, the frequency is approximately 20-50% of T lymphocytes
(Brennan et al., 2013; Salio et al., 2014a). In humans, the distribution of iNKT cells is
more variable and typically less frequent in the liver and other peripheral organs than in
mice; in peripheral blood, human iNKT cells range from approximately >0.001% to 3%.
Although the relative frequency of iNKT cells is low, they have potent immunomodulatory
roles in many diseases, including cancers, autoimmune diseases, and viral infections
(Bendelac et al., 2007a). The focus of this thesis concerns the role and activity of iNKT
cells with regard to anti-tumor immunity. These anti-tumor functional properties and the
therapeutic use of iNKT cells for cancer immunotherapies are described in more detail in
the sections below.

1.3. Anti-tumor properties of iNKT cells
iNKT cells play important roles in anti-tumor immunity that have been
increasingly elucidated and appreciated over the past several years in many different
contexts. In human patients, the frequencies of circulating iNKT cells have been shown
to correlate with reduced tumor progression and improved survival in many different
cancer types, including prostate, medulloblastoma, melanoma, multiple myeloma, colon,
lung, breast, and head and neck squamous carcinoma (Exley et al., 2011; Wolf et al.,
2018). In neuroblastoma, a pediatric solid embryonal tumor, iNKT cell frequencies within
6

the tumor itself are associated with better 5-year survival and prognosis (Hishiki et al.,
2018; Metelitsa et al., 2004).
In addition to this correlative data, further evidence for the role of iNKT cells in
tumor immunosurveillance has been demonstrated in several mouse models. In mice
lacking one allele of the tumor suppressor p53 (p53+/-) and thus more susceptible to
tumor formation, those lacking iNKT cells were more prone to tumor development
relative to mice with iNKT cells (Swann et al., 2009). Similarly, treatment of CD1d-/- or
Jα18-/- mice (which lack iNKT cells) with the carcinogen methylcholanthrene resulted in
greater incidence of tumors and higher tumor burdens relative to wild-type mice.
Conversely, the transfer of iNKT cells into tumor-bearing mice Jα18-/- was sufficient to
protect them from tumor formation (Bellone et al., 2010). Furthermore, our lab previously
showed that injection of purified NKT cells into lymphocyte-deficient NOD-Scid-IL2rg-/(NSG) mice was sufficient to protect these mice upon challenge with a CD1d+ tumor
(Bassiri et al., 2014).

Indirect iNKT cell anti-tumor immunity
As mentioned above, iNKT cells are activated upon encounter with CD1dglycolipid antigen complexes. The activation of iNKT cells is further enhanced by costimulatory signals from a number of molecules downstream from the TCR receptor,
including CD28, CD137 (4-1BB), CD40L, CD278 (ICOS), and NKG2D, which contribute
to the robust iNKT cell response (Kaneda et al., 2005; Kuylenstierna et al., 2011; Vinay
et al., 2004; Wang et al., 2009, 2013). Additionally, iNKT cells can also be activated
through exposure to the cytokines IL-12 and IL-18, irrespective of TCR-mediated
interactions (Reilly et al., 2010; Tyznik et al., 2008).
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Upon activation, iNKT cells engage in potent production of many cytokines and
chemokines that consequently recruit and activate many other immune populations to
form a robust anti-tumor response. Like innate NK cells, iNKT cells possess pre-formed
cytosolic mRNA for cytokines including IFN-g and IL-4, enabling them to secrete
cytokines rapidly upon activation (Stetson et al., 2003), unlike conventional T cells that
require prior priming. iNKT cells can be classified into subtypes based on their cytokine
profiles, akin to the Th1, Th2, and Th17 cytokine subsets in conventional T cells
(Brennan et al., 2013; Crosby and Kronenberg, 2018). Th1-like iNKT cells, regulated by
the T-bet transcription factor, predominantly produce pro-inflammatory cytokines
including IFN-g, TNF-α, and IL-2, and have enhanced cytotoxic capacity. Conversely,
NKT2 cells – analogous to Th2 T cells – produce more regulatory cytokines, including IL4 and IL-13, and are demarcated by expression of the transcription factor GATA-3.
Additionally, NKT17 cells, which express the transcription factor RORgt, produce IL-17,
akin to Th17 T cells. Finally, it has also been shown that TGF-β – an
immunosuppressive cytokine – can induce the differentiation of Foxp3+ iNKT cells that
resemble regulatory T cells (TREG) (Monteiro et al., 2010). The distributions of these iNKT
cell subtypes within tumors could influence the immune responses within the tumor
microenvironment. Indeed, the type of cytokines produced by iNKT cells is largely
dependent on the avidity of CD1d-glycolipid antigen interaction with the iNKT cell TCR
receptor (Hung et al., 2017), which can be modulated by the type of stimulatory
glycolipid antigen presented – α-GalCer tends to produce a Th1-like response
predominated by IFN-g, while OCH, a synthetic analog of αGalCer with a truncated lipid
chain, elicits a Th2-like response predominated by IL-4 production (Sullivan et al., 2010).

8

In the context of tumor immunosurveillance, the production of IFN-g, IL-12, and
IL-2 by iNKT cells activates the proliferation and IFN-g secretion of NK cells (Carnaud et
al., 1999; Iyoda et al., 2018; Metelitsa et al., 2001). Additionally, these iNKT cellsecreted cytokines also mature and activate dendritic cells (DCs) (Fujii et al., 2007),
which in turn activate CD8+ T cells (Fujii et al., 2003). This results in a feed-forward loop
whereby iNKT cells upregulate surface IL-12 receptor expression and CD40L upon
activation, which in turn induces maturation and production of IL-12 in DCs, and this IL12 then induces IFN-g production in iNKT cells, conferring a robust Th1 immune
response (Brennan et al., 2013). Furthermore, cytokines produced by iNKT cells can
also restore the activity of immune cell function. In both a mouse model and in human
patient samples from an MHC I-deficient tumor containing exhausted NK cells
(characterized by upregulated Tim3 and PD-1 negative checkpoint receptors and loss of
IFN-g production and cytotoxic function), IL-21 secreted by iNKT cells restored NK cell
function to reduce tumor growth (Seo et al., 2017). Similarly, in a humanized xenograft
model of melanoma resistant to inhibition of PD-1, iNKT cell secretion of IL-2 and IL-12
was found to re-invigorate exhausted CD8+ T cells to confer reduced tumor burden and
improved survival (Bae et al., 2018). Finally, in addition to activating the anti-tumor
activity of pro-inflammatory immune cells, iNKT cells can also inhibit the
immunosuppressive activity of pro-tumorigenic immune cells. By secretion of
granulocyte-macrophage colony stimulating factor (GM-CSF), iNKT cells can inhibit
myeloid-derived suppressor cells (MDSCs) and reprogram tumor-associated
macrophages (TAMs) to display a more pro-inflammatory (M1) phenotype (Mussai et al.,
2012; Song et al., 2009).
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Direct iNKT cell cytotoxicity
In addition to cytokine-mediated anti-tumor activity, iNKT cells are also capable
of inducing direct cytotoxicity of CD1d+ tumor targets, both in vitro and in various murine
tumor models. Upon recognition of tumor targets, iNKT cells can mediate cytotoxic
release and killing via secretion of perforin and granzymes. Indeed, earlier work
demonstrated that iNKT cells were sufficient to control growth of a CD1d-expressing T
cell lymphoma through the SAP adaptor protein and perforin-mediated tumor lysis (Das
et al., 2013). Alternatively, iNKT cells can also exert cytotoxicity via upregulation of Fas
ligand (FasL; CD178) (Wingender et al., 2010) and TNF-related apoptosis inducing
ligand (TRAIL; CD253) (Bassiri et al., 2013). Additionally, iNKT cells have also been
shown to induce cytotoxicity by ligation of NKG2D via stress ligands expressed on target
cells, which can then co-stimulate TCR-mediated cytotoxicity as well (Kuylenstierna et
al., 2011). Finally, in addition to targeting tumor cells expressing CD1d, iNKT cells can
also further engage anti-tumor cytotoxicity through killing of CD1d-expressing tumorassociated macrophages (TAMs); in neuroblastoma tumors, this mechanism was
demonstrated to suppress tumor growth (Song et al., 2009). Thus, iNKT cells are
capable of exerting numerous mechanisms of direct cytotoxicity of tumor targets that
could be harnessed for use in immunotherapies.

Approaches to activating iNKT cell activity in pre-clinical models
Given the potent anti-tumor properties of iNKT cells and their unique ability to
bridge innate and adaptive immunity, many different therapeutic strategies harnessing
iNKT cell activity have been developed and tested in preclinical stages. To directly and
specifically activate NKT cells towards tumor targets, the Donda laboratory group
developed a soluble CD1d fusion molecule directed towards tumor-specific antigens,
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akin to bispecific engager molecules that have been clinically utilized for cancer therapy
to specifically activate immune effector populations. The goal of this approach was to
specifically activate NKT cells even when the tumors themselves do not express CD1d
on their surface. Specifically, they designed a conjugate molecule comprised of a
recombinant soluble CD1d (sCD1d) loaded with α-GalCer fused to a tumor-targeted
single-chain variable antibody fragment (scFv) specific for HER2 (Stirnemann et al.,
2008). They found that the full protein (sCD1d-anti-HER2) effectively activated NKT cells
in vivo and reduced tumor burden of HER2-expressing lung tumors. Notably, the effect
was NKT-cell specific, as the sCD1d-anti-HER2 molecule was unable to inhibit tumor
growth of HER2-expressing tumor cells injected into CD1d-/- mice lacking NKT cells.
Furthermore, not only did the iNKT cells effectively home to the tumors upon activation
with the conjugate antibody, but also transactivated NK cells and promoted DC
maturation (Stirnemann et al., 2008). They also validated these findings by performing
repeated stimulations and looking longer-term in vivo to see if the iNKT cells mediated a
sustained immune response or whether they would become anergic upon chronic
stimulation and lose functionality. Interestingly, they found that multiple injections of this
fusion protein induced sustained iNKT cell activation, demonstrated by high levels of
IFN-g production and tumor regression relative to the control groups comprised of αGalCer-CD1d alone or α-GalCer-CD1d fused to an antibody targeting an irrelevant
antigen (Corgnac et al., 2013). Similar to these studies, another group demonstrated that
a conjugate molecule comprised of an α-GalCer-loaded CD1d soluble protein fused to
CD19 could effectively induce specific iNKT cell cytotoxicity against CD19+ tumor targets
in vitro and in vivo (Das et al., 2019). Together, these studies demonstrate the ability to
specifically promote and sustain iNKT cell activation towards tumor targets, which may
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be a therapeutically beneficial approach particularly within tumors that either do not
naturally express CD1d or downregulate CD1d expression as an escape mechanism.
Another recent antibody-based approach to activate iNKT cells that also
circumvents the need for tumor cells to express CD1d is the use of monoclonal
humanized antibodies that specifically bind to the invariant TCR (iTCR) to induce iNKT
cell activity. These have been primarily investigated by the labs of Kim Nichols and
Rupali Das (in conjunction with the company NKT Therapeutics, Inc.) as an approach to
engage murine and human iNKT cell activity. They first tested NKTT320, a recombinant
humanized monoclonal antibody that selectively binds to iTCRs with high affinity. Both
soluble and immobilized (plate-bound) NKTT320 induced robust human iNKT cell
activation, demonstrated by secretion of Th1 and Th2 cytokines, degranulation,
proliferation, and transactivation of bystander immune cells including NK cells (Patel et
al., 2020). Another novel monoclonal antibody, NKT14m, was designed to target mouse
iNKT cells (Scheuplein et al., 2015). This antibody demonstrated efficacy in inducing
murine iNKT cell anti-tumor immunity towards B cell lymphoma tumor targets both in
vitro and in vivo (Escribà-Garcia et al., 2019). Indeed, in a recent follow-up, it was found
that NKT14m in conjunction with low-dose IL-12 resulted in significantly enhanced iNKT
cell cytokine production and inhibited tumor growth in vivo (Guan et al., 2020).
Collectively, these antibody therapies represent a potential novel therapeutic
strategy for the activation of iNKT cell activity within tumors. While these studies have
currently only been conducted in mouse models and thus remain in pre-clinical stages,
there could be therapeutic efficacy in patients that warrants further investigation,
particularly in combination with other therapeutic approaches that modulate additional
immune effector cells in the tumor microenvironment. Finally, another therapeutic
strategy to activate iNKT cells is the use of chimeric antigen receptor (CAR)-transduction
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to specifically provide iNKT cells the ability to target tumor-specific antigens. In
neuroblastoma, this approach was designed and tested first in a xenograft mouse model
and is now in an early clinical trial in human patients – this is further discussed in the
next section.

1.4. Clinical use of NKT cell-based immunotherapies for cancer
The potent and diverse anti-tumor effector mechanisms exerted by iNKT cells
makes them potentially desirable immune effector cells for the design of more effective
cell-based tumor immunotherapy platforms. Particularly in solid tumors, where there is a
great need for more effective immunotherapeutic strategies, harnessing iNKT cell activity
could provide therapeutic benefit. One advantage offered by iNKT-cell based therapies,
in contrast to T cells, is that because they recognize CD1d which is monomorphic, they
do not induce graft-versus-host disease (GvHD). This may allow for a safe, allogeneic,
off-the-shelf cellular immunotherapy that could overcome challenges faced by T-cell
based immunotherapies. Additionally, iNKT cells engage multiple mechanisms of
cytotoxicity and their innate-like professional killing abilities could be very advantageous
to employ for therapeutic benefit.
Many iNKT cell-based strategies have begun to be utilized and demonstrate
some promise for the treatment of tumors. However, these currently remain in very early
clinical stages overall, and it remains to be seen long-term how well iNKT-cell based
immunotherapies perform, as well as how to best expand and engineer these cells for
solid tumor immunotherapies. These areas are further discussed in Chapters 3 and 4.
Nevertheless, the current approaches being utilized are discussed below.

alpha-GalCer stimulation of iNKT cell activity
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Given the preclinical evidence that α-GalCer induces iNKT strong anti-tumor
responses (discussed in section 1.3), several phase I trials of α-GalCer (KRN7000)
administration were tested in late-stage cancer patients. In the first study (Giaccone et
al., 2002) of 24 patients with advanced-staged solid tumors, a subset of patients
demonstrated an increase in cytotoxicity, serum cytokine levels (GM-CSF and TNF-α),
and peripheral NK cell levels; however, the numbers of circulating iNKT cells were
diminished 24 hours after injection, and only patients with high enough starting numbers
of iNKT cells displayed a clinical response.
To circumvent the issues of low circulating iNKT cell numbers, α-GalCer-loaded
dendritic cells (DCs) were developed as an alternative approach to inducing iNKT cell
anti-tumor responses. The first clinical trial of autologous mature CD1d-expressing
monocyte-derived DCs pulsed with α-GalCer was comprised of twelve patients with a
variety of metastatic cancers (i.e. melanoma, liver cancer, renal cell carcinoma, and
prostate carcinoma, and lung adenocarcinoma) (Nieda et al., 2004). This study found
that a subset of patients displayed a robust immune response, including sustained NKT
responses, serum levels of anti-tumor cytokines, and activation of NK cells, T cells, and
B cells, ultimately demonstrating clinically that iNKT cells can effectively bridge innate
and adaptive responses. Shortly afterwards, other groups performed autologous
transfers of α-GalCer-pulsed DCs in advanced cancers and were able to detect robust
numbers of circulating iNKT cells with minimal side effects or toxicity, and in some
cases, disease stabilization (Chang et al., 2005; Ishikawa et al., 2005). Subsequent
clinical trials utilized adherent monocytic cells treated with GM-CSF and IL-2 to load αGalCer; in one, the presence of activated intratumoral iNKT cells within the tumor
microenvironment was confirmed (Nagato et al., 2012), and others demonstrated some
success for the treatment of lung cancer and head and neck cancer – specifically in that
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prolonged survival was achieved for a small number of patients (Motohashi et al., 2009).
In a recent phase II update of 35 non-small cell lung cancer patients receiving α-GalCerpulsed antigen presenting cells (APCs), fourteen patients had stabilized disease and one
had a partial response, while the others succumbed to disease progression; an increase
in IFN-g producing cells (including NK cells) was also detected (Toyoda et al., 2020).
Overall, these early trials demonstrate moderate therapeutic potential for a small
subset of patients, as well as no severe adverse effects, indicating that iNKT cell-based
therapies have the potential to be safe and effective. However, one of the major
drawbacks of these studies was that the degree of clinical response achieved was
largely dependent on the levels of NKT cells prior to treatment; often, these numbers
were too low to sustain durable responses in large numbers of patients. Thus, the use of
cellular therapies that do not rely on endogenous numbers of circulating iNKT cells in
patients may be more beneficial moving forward.

Adoptive transfer of iNKT cells
To achieve higher numbers of iNKT cells in cancer patients, a complementary
approach to α-GalCer stimulation is to adoptively transfer iNKT cells directly, which has
been tested in several phase I and II clinical trials to date. The first study expanded
PBMCs in culture using repeated stimulation via α-GalCer and infused the stimulated,
iNKT-enriched bulk cells into six patients with non-small cell lung cancer (Motohashi et
al., 2006). Using this approach, there were no partial or complete responses, and the
boost in iNKT cell number was only transient, but this group did demonstrate the safety
of this approach in that no adverse effects were reported. Following this, another study
combined the use of α-GalCer-loaded DCs with infusion of autologous, iNKT-cell
enriched PBMC product (Kunii et al., 2009). In the phase I trial, some patients displayed
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partial responses or stabilized disease; in phase II trials, of the ten patients with head
and neck squamous carcinoma, five experienced stable disease and the other five a
partial response, with an increase in both circulating and intratumoral iNKT cell numbers
in 90% of the patients and minimal side effects (Yamasaki et al., 2011a). Finally, most
recently, a phase I clinical trial by Exley et al. (2017) of autologous expanded and
purified iNKT cells in nine melanoma patients found that three patients demonstrated
partial or complete responses, but six eventually succumbed to disease progression.
This study was the first to infuse large cell populations with high iNKT cell purity –
specifically, three doses of 250 million iNKT cells each.
Overall, we can conclude from these trials that the adoptive transfer of iNKT cells
could potentially be an effective therapeutic approach in that it is generally safe and welltolerated. However, additional methods of ex vivo expansion and stimulation to reliably
obtain large numbers of functional iNKT cells are still needed to achieve better efficacy.
Additionally, it is still not fully known how effectively iNKT cells traffic to, infiltrate, persist,
and function within solid tumors. Finally, all of these trials were conducted with
autologous cells in small numbers of patients, so it would be clinically beneficial to test
allogeneic approaches that allow for greater scalability of cells to ultimately enable the
treatment of a higher volume and range of patients. One potential solution to this could
be the use of hematopoietic stem cell (HSC)-derived iNKT cells, which were recently
demonstrated to effectively expand and traffic to tumors in two different murine tumor
models (Zhu et al., 2019). This approach is further discussed in Chapter 4.

Use of chimeric antigen receptor (CAR)-transduced iNKT cells
Finally, an iNKT-cell based immunotherapy platform that may be very
therapeutically effective is the use of CAR-transduced iNKT cells. In T cells, the
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expression of CARs directed towards CD19 have demonstrated high efficacy for
hematological malignancies and have been clinically approved for usage in patients
(Ahmad et al., 2020). However, in solid tumors, CAR-T cell immunotherapies have had
more limited therapeutic efficacy, as they face several major challenges including: 1)
adverse effects of allogeneic therapies including GvHD; 2) durability of the anti-tumor
response; and 3) persistence within the tumor microenvironment (TME).
With regard to GvHD, iNKT cells may possess an advantage over the use of
conventional T cells, in that iNKT cells have been demonstrated to suppress GvHD and
are associated with reduced levels of GvHD clinically (Chaidos et al., 2012; Dellabona et
al., 2011; Guan et al., 2016; Pillai et al., 2007), suggesting that they may be a safer
cellular therapy option, particularly for immunocompromised patients. Furthermore, as
discussed in section 1.3, iNKT cells are capable of nucleating multiple mechanisms of
anti-tumor cytotoxicity, which may maximize their ability to mount stronger and more
diverse anti-tumor immunity relative to conventional T cells. For instance, iNKT cells
could kill CD1d-expressing tumor cells or CD1d-expressing tumor-associated
macrophages upon TCR activation, while also enabling enhanced NK cell and T cell
responses. Collectively, this could serve as a multi-fold iNKT cell response that
maximizes both the number of cells targeted and amount of tumor regression response
achieved.
Finally, with regard to persistence within the TME, it is not yet understood how
well iNKT cells adapt to survive and retain function long-term within the TME, especially
relative to T cells – this is the major focus of this dissertation and rationale for the need
to better understand iNKT cell immunometabolism, which will be introduced in Chapter 2
and experimentally investigated in Chapter 3.
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To address some of the challenges faced by CAR-T-cell based immunotherapies
for solid tumors and demonstrate whether CAR-transduced iNKT cells could be
efficacious, the Metelitsa group (Heczey et al., 2014) designed and tested the efficacy of
CAR-iNKT cells targeted against GD2, a disialoganglioside expressed by
neuroblastoma. In their first proof-of-concept study, they engineered primary human
PBMC-derived iNKT cells with several CAR-GD2 constructs, encoding CD3z chain alone
or in addition to either CD28, 4-1BB, or both CD28 and 4-1BB co-stimulatory domains.
They found that these CAR iNKT cells were able to expand effectively in culture and
dose-dependently engaged anti-tumor cytotoxicity against both CD1d+ and CD1d- GD2expressing neuroblastoma targets in vitro (thus engaging both endogenous TCR
activation as well as GD2-induced activation). In particular, the 4-1BB CAR endowed the
iNKT cells with a Th1 cytokine profile, secreting high levels of IFN-g and GM-CSF;
importantly, in an in vivo metastatic neuroblastoma xenograft model, the CD28-4-1BB
construct was able to localize to the tumor site and exert potent antitumor activity to
achieve tumor regression and enhance host survival. Moreover, the CAR-iNKT cells
persisted within the tumors and did not induce any notable adverse effects such as
GvHD. This proof-of-concept study provided the rationale for utilizing these CAR-iNKT
cells in human NB patients for the first time in a phase I clinical trial. Recently, an interim
update of this trial on the first three patients – all of whom had metastatic neuroblastoma
and received anti-GD2-CAR treatment – was reported (Heczey et al., 2020). In all three
patients, the CAR-iNKT cells were detected at higher than baseline peripheral
frequencies and appeared to persist for the full evaluation period of several weeks;
furthermore, no major toxicities were observed. In two out of the three patients, disease
was stabilized and in one patient, partial response was achieved.
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Overall, it appears so far that iNKT cells can be expanded to clinical scale with
high purity and effective tumor trafficking to safely treat patients with solid tumors such
as neuroblastoma. Future studies in larger numbers of patients will provide a better
indication of how to best tailor their clinical efficacy. Additionally, a better understanding
of how iNKT cells persist within the solid TME long-term, and what factors predict better
adaptability and survival in these cells, is imperative. While this remains unknown in
human patients, a study in a murine model of brain lymphoma that compared CAR-iNKT
cells side-by-side with CAR-T cells directed towards the same antigen (CD19) indicated
that the CAR-iNKT cells more effectively infiltrated and persisted within tumors, resulting
in better tumor regression and survival (Rotolo et al., 2018). Although this was
investigated in a mouse model, it supports the notion that iNKT cells could both exert
more potent anti-tumor activity through dual targeting of CD1d tumor targets and tumorspecific targets, as well as possess better adaptability and persistence within the TME.
Ultimately, similar studies in human patients would be of great value, in addition to a
better understanding of properties governing persistence within the TME in iNKT cells,
such as immunometabolism. This topic is examined in the context of T cells in Chapter
2, investigated in iNKT cells in Chapter 3, and discussed more extensively in Chapter 4.
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CHAPTER 2: DISSECTING THE LINK BETWEEN METABOLISM AND FUNCTION OF
T LYMPHOCYTES
2.1. T cell differentiation states are characterized by distinct metabolic programs
Cells are continually sensing their environment to adapt to extracellular signals
and acquire necessary nutrients in order to support basic functions and survival. The
bioenergetic demands of immune cells in particular are dynamic, as different nutrients
and metabolic pathways are required for survival and homeostasis, activation, growth,
proliferation, and exerting effector functions. To support these dynamic cellular states
and functions, cells may engage in anabolic metabolic processes, by which they
synthesize fundamental macromolecules from individual building blocks such as
carbohydrates, amino acids, lipids, and nucleotides to fuel cellular growth; alternatively,
immune cells may also utilize catabolic processes to break down macromolecules into
these individual components in order to generate adenosine triphosphate (ATP) required
for homeostatic functions and proliferation. Importantly, these processes can be very
dynamic and not only vary by a cell’s activation state, but also extracellular cues and
signals from other interacting cells.
It is now well-appreciated that the distinct differentiation states and functional
status of T cells are associated with their underlying metabolism. Briefly, quiescent naïve
T cells primarily utilize oxidative phosphorylation (OXPHOS) to generate ATP to
maintain homeostasis. Upon activation, these cells differentiate into effector T cells,
shifting to rely predominantly on glucose and glutamine metabolism to fuel effector
functions and cell growth. Finally, a small pool of activated T cells differentiates into
memory T cells; these cells, which are primed to be re-activated rapidly upon secondary
encounter with antigen, primarily utilize mitochondrial metabolism and fatty acid
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oxidation (FAO). These different differentiation states and associated metabolic
pathways will be discussed at length in the sub-sections below.

Naïve T cell metabolism
As T cells exit the thymus, their predominant role as resting naïve cells is to
migrate through secondary lymphoid tissues to survey for cognate antigens in order to
become activated (MacIver et al., 2013). These resting cells are very small in size and
arrested in the G0 phase of the cell cycle; therefore, their predominant energy needs are
to support cytoskeletal rearrangements to migrate through the body and maintain basic
cellular homeostasis and survival (Hamilton and Jameson, 2012). To accommodate their
basic energy demands, naïve T cells require ATP production and thereby rely
predominantly on OXPHOS metabolism. Specifically, in the presence of oxygen,
pyruvate derived from glycolysis first enters the citric acid cycle, or tricarboxylic acid
(TCA) cycle (also referred to as the Krebs cycle), where it is converted to acetyl
coenzyme A (acetyl CoA) and through several steps in the mitochondria, generates
NADH and FADH2; these end products supply electrons to the electron transport chain
(ETC), which through the process of OXPHOS efficiently generate high amounts of ATP.
Though naïve T cells are relatively quiescent, they actively maintain this state
through signaling via interleukin 7 (IL-7) and their T cell receptor (TCR) (Marrack and
Kappler, 2004). IL-7 is a pro-survival factor for naïve T cells, signaling through IL-7
receptor (IL-7R) to inhibit apoptosis (Jacobs et al., 2010; Tan et al., 2001). Additionally,
IL-7R regulates glucose uptake through PI3K/Akt/mTOR pathway signaling to promote
trafficking of the glucose transporter Glut1 (Wofford et al., 2008). TCR signaling is also
important for naïve T cell homeostasis and metabolism, as it promotes glucose uptake
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and baseline Glut1 expression that supports the ATP production needed for these cells
(Barata et al., 2004; Rathmell et al., 2001).
Additionally, the mechanistic target of rapamycin (mTOR) protein complexes are
important cellular nutrient sensors and metabolic regulators. In naïve T cells specifically,
loss of the tumor suppressor Tsc1 – an inhibitor of the mTORC1 complex – results in
mTORC1 activation, which in turn promotes higher glycolysis, cell growth, and entry into
the cell cycle (Yang et al., 2011); collectively, this disrupts naïve T cell homeostasis.
Another signaling axis that contributes to maintaining the naïve T cell pool is adenosine
2A receptor (A2AR), which decreases sensitivity to TCR signaling to prevent activation
and promote naïve T cell homoeostasis and survival (Cekic et al., 2013). Taken
together, naïve T cells actively maintain their resting state and quiescent metabolism
through regulatory signaling mechanisms.

Effector T cell metabolism
Once naïve T cells encounter cognate antigen presented by major
histocompatibility complex (MHC) molecules expressed on antigen-presenting cells, an
immune synapse forms and TCR clustering and signaling is induced. This CD3
stimulation (“signal 1”) followed by co-stimulation from CD28 (“signal 2”) fully activates T
cells, differentiating them into effector T cells. As this occurs, cellular changes are
induced that are associated with a shift in global transcriptional profiles, such that
quiescent gene pathways are shut down while activation genes and pathways are
upregulated (Teague et al., 1999; The Immunological Genome Project Consortium et al.,
2013). As T cells are stimulated, they undergo rapid cell growth, proliferation (i.e. cell
cycle progression), and exert effector functions, including cytokine production and
cytotoxicity. To support these functional changes, the metabolic requirements of
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stimulated T cells shift such that these cells increasingly depend on biosynthesis of
intracellular building blocks such as nucleic acids, lipids, and proteins. In order to meet
these demands, T cells undergo metabolic reprogramming, whereby they upregulate
glucose and glutamine metabolism and decrease lipid catabolism (MacIver et al., 2013;
Wang et al., 2011). Indeed, this increased reliance on glycolysis was first observed by
Otto Warburg, who observed that cancer cells – in spite of oxygen availability –
preferentially utilize aerobic glycolysis to support rapid proliferation (Warburg, 1956a,b).
As such, as glucose is metabolized through glycolysis to form pyruvate, this pyruvate is
converted into lactate rather than entering the TCA cycle and undergoing OXPHOS. In
addition to malignant cells, this “Warburg effect” was discovered to be true of activated T
lymphocytes as well (Bental and Deutsch, 1993). Although glycolysis is less efficient at
generating ATP, it provides proliferating cells with building blocks to synthesize lipids,
nucleic acids, and proteins that support cell growth and effector functions. Specifically,
glycolytic intermediates feed into the pentose phosphate pathway, serine biosynthesis
pathway, and generate acetyl-CoA, which through the TCA cycle feeds into lipid
synthesis – together, these pathways support the generation of biomass to support cell
growth (O’Neill et al., 2016).
One of the major metabolic changes induced by TCR activation is an increase in
glucose transporter (GLUT transporter family) expression and trafficking to the cell
surface to allow for enhanced and rapid glucose influx into the cell. Specifically, resting T
cells express Glut2 and Glut3, while effector T cells induce expression of Glut1,
mediated by CD28-dependent PI3K/Akt signaling (Frauwirth et al., 2002). Indeed, this
has been shown to be required for proper T cell activation, as murine T cells deficient in
Glut1 are unable to survive or proliferate upon activation (Macintyre et al., 2014), while
transgenic expression of Glut1 increases cytokine production and proliferation (Jacobs
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et al., 2008). In addition to uptake of glucose, effector T cells also increase the uptake of
amino acids and the expression of these nutrient transporters on the cell surface. For
instance, Slc7a5, a subunit of transporters that regulate uptake of large and branched
amino acids, is highly upregulated in murine CD4+ and CD8+ T cells upon activation
(Sinclair et al., 2013). Furthermore, glutamine is another key nutrient essential for T cell
activation, and expression of Slc1a5 (ASCT2) – a glutamine transporter – is essential for
T cell effector functions (Nakaya et al., 2014a).
A key post-transcriptional regulator of glycolytic metabolism upon activation is
mTOR. Upon co-stimulatory signaling induced via CD28, PI3K becomes activated, which
in turn activates Akt (Frauwirth et al., 2002). Once Akt is phosphorylated, a signaling
cascade is initiated whereby mTORC1 is activated, leading to promotion of aerobic
glycolysis. These protein complexes facilitate the initiation of glycolytic metabolism
through a number of mechanisms (MacIver et al., 2013). Akt and mTOR promote
trafficking of Glut1 to the cell surface and prevent its internalization upon T cell
stimulation, thereby allowing for enhanced glucose uptake (Rathmell et al., 2003).
Furthermore, Akt promotes the trafficking of additional amino acid transporters to the cell
surface as well (Edinger, 2007; Edinger and Thompson, 2002). In addition, Akt can
directly phosphorylate glycolytic enzymes, including hexokinase II (HK2) to enhance its
enzymatic activity (John et al., 2011; Miyamoto et al., 2008) – although this has been
demonstrated in non-immune cells, Akt may likely employ a similar mechanism in
activated T cells to promote glycolytic flux. mTORC1 also phosphorylates the proteins
4EBP and p70s6 kinase, which enhance protein translation, facilitating cell growth
(Tandon et al., 2011). Finally, Akt and mTORC1 also activate SREBP2 to both increase
lipid synthesis and downregulate lipid catabolism via reducing expression of carnitine
palmitoyl transferase (Cpt1a), the rate-limiting enzyme of FAO (DeBerardinis et al.,
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2006; Porstmann et al., 2008). The importance of mTORC1 for T cell activation and
effector differentiation is underscored by studies in which inhibition of mTORC1 activity
inhibits stimulation-induced glycolytic reprogramming and results in blocked T cell
growth, proliferation, and effector functions (Pollizzi et al., 2015; Powell and Delgoffe,
2010).
The increase in glycolysis by effector T cells is also facilitated by transcriptional
regulators. One of the most notable transcriptional regulators of T cell metabolic
reprogramming upon stimulation is the oncogenic Myc family of transcription factors.
Myc proteins form heterodimers with the transcription factor Max, and together, these
heterodimers bind to E-box regulatory regions of DNA to regulate the expression of
many genes involved in the cell cycle and metabolism (Dang et al., 1999). The role of
Myc proteins in transcriptionally regulating cell growth and proliferation was first
observed in tumor cells. Since then, it has also been found that c-Myc specifically is
predominantly expressed in stimulated cells including T cells, and indeed, is critical for
development, as c-Myc knockout mice are embryonic lethal (Douglas et al., 2001; Kelly
et al., 1983). In 2011, a key paper identified the early metabolic transcriptional changes
induced by TCR stimulation of CD4+ and CD8+ T cells (Wang et al., 2011). Notably, they
found that after 24 hours of stimulation, T cells upregulated genes encoding key
enzymes in glycolysis and glutamine catabolism pathways; conversely, in nutrient-free
media conditions, activation-induced cell growth, proliferation, and progression through
the cell cycle was abrogated. Importantly, the metabolic reprogramming induced by
stimulation was dependent upon Myc; T cells with acute Myc depletion were unable to
grow or proliferate, displaying significantly lower levels of lipids, nucleotides and amino
acids, reduced expression of cell cycle regulator genes, and impaired glycolytic flux and
glutamine oxidation. Myc was specifically important for glycolysis and glutaminolysis, as
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flux through other pathways such as pyruvate metabolism, fatty acid oxidation, and
oxygen consumption were not sensitive to Myc depletion (Wang et al., 2011).
While Myc is required for the early metabolic switch in T cells upon activation (24
hours) for proliferation, other factors are important for sustaining this activation and
regulating glycolytic metabolism once Myc expression diminishes. One example is
hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that is also
induced by TCR activation. Under normoxic conditions, HIF-1 is degraded by the tumor
suppressor VHL; however, in hypoxic conditions, HIF-1 becomes stabilized (Semenza,
2001). In addition to Myc, HIF1-α has also been shown to regulate expression of
glycolytic enzymes (Kaelin, 2005). While Myc is required for activation-induced
proliferation, HIF-1α is dispensable for proliferation (Finlay et al., 2012) – however, HIF1α appears to be more important for effector functions, as HIF1-α regulates differentiation
of both CD4+ and CD8+ T cells (Doedens et al., 2013; Lukashev et al., 2006) and
promotes differentiation into Th17 T cells (Dang et al., 2011).
Beyond the observations that T cell activation is associated with upregulated
glucose metabolism and glycolytic flux, several studies have demonstrated both the
requirement for glucose for effector functions and mechanistically, how glycolytic flux is
directly linked to T cell function. Early studies in the field found that depletion of glucose
in media impairs the ability of T cells to produce IFN-g (but not IL-2) (Cham and
Gajewski, 2005). Furthermore, CD8+ effector T cells treated with 2-deoxy-D-glucose (2DG), which inhibits glycolysis, displayed lower production of IFN-g and GM-CSF
cytokines, reduced cell cycle progression, and reduced granzyme B and cytolytic activity
(Cham et al., 2008), together highlighting the importance of glucose metabolism for T
cell effector functions. Furthermore, it was also discovered that GAPDH – a glycolytic
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enzyme – when not being utilized for glycolysis (i.e. in the absence of glucose) binds to
the regulatory 3’untranslated region (UTR) of Ifng mRNA transcripts to prevent
translation (Chang et al., 2013). Conversely, T cells were able to maintain survival and
proliferation without aerobic glycolysis, indicating a specific role for this pathway for
cytokine production. An additional study also demonstrated that lactate dehydrogenase
A (LDHA) in effector T cells – which converts pyruvate to lactate in aerobic glycolysis –
promotes IFN-g expression on an epigenetic level, by histone acetylation of the Ifng
promoter (Peng et al., 2016). Collectively, these findings demonstrate mechanistically
how glycolysis is directly linked to promoting effector cytokine production.
In addition to glucose, glutamine has also been implicated as a key nutrient for T
cell activation-induced effector functions. Glutamine is abundant in serum and used in
many different metabolic pathways (DeBerardinis and Cheng, 2010). Glutamine can
serve as an amine group donor for purine and pyrimidine nucleotide synthesis, and can
also be metabolized into glutamate; glutamate subsequently enters the TCA cycle as it is
converted to α-ketoglutarate. This conversion into TCA intermediates can facilitate
downstream energy production and promote fatty acid synthesis as well. Upon TCR
stimulation, T cells upregulate Slc1a5, Slc38a1, and Slc38a2, which are transporters that
facilitate glutamine uptake into the cell (Bhutia and Ganapathy, 2016; Carr et al., 2010;
Nakaya et al., 2014a). Activated T cells also upregulate the expression of many other
glutamine metabolism genes, including glutaminase 2 (Gls2) in a Myc-dependent
manner (Wang et al., 2011). Additionally, glutamine metabolism upon activation is
dependent on signaling from the ERK protein, downstream of MAPK signaling (Carr et
al., 2010). In terms of functional importance, glutamine depletion in vitro significantly
impairs T cell proliferation and secretion of IFN-g and IL-2 cytokines (Carr et al., 2010).
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Interestingly, it was shown that in glucose-depleted conditions, glutamine was required
for ATP production in effector T cells (Blagih et al., 2015), which suggests that glutamine
could potentially be able to compensate for some glucose-dependent effector functions
in activated T cells. Overall, glucose and glutamine, as well as other amino acids,
appear to be critical for the functional changes induced by effector T cell differentiation
upon TCR stimulation. While our understanding of the immunometabolic features of
TCONV in different conditions has significantly increased in the past two decades, the
mechanisms that govern T cell metabolic flexibility to allow these cells to adapt to
nutrient-depleted conditions is not well understood.

Memory T cell metabolism
Following antigen encounter and activation, many effector T cells succumb to
apoptotic cell death. However, a small pool of these activated lymphocytes differentiates
into memory T cells, which are long-lived cells specialized for rapid reactivation and
effector response upon secondary encounter with cognate antigen. Thus, the primary
functions of memory T cells are to efficiently generate energy to maintain survival longterm and to possess rapid recall ability and self-renewal. To support these functions, the
metabolic demands of these cells shift, inducing another metabolic reprogramming.
Memory T cells, differentiated from cytotoxic CD8+ T cells, no longer rapidly grow
and instead, possess a more quiescent phenotype governed primarily by catabolic FAO
metabolism (Klein Geltink et al., 2018). Indeed, memory T cells express high levels of
carnitine palmitotyltransferase 1A (Cpt1a), the rate limiting enzyme of FAO that imports
long-chain fatty acids from the cytosol into the mitochondria to be oxidized into the TCA
cycle. Importantly, inhibition or knockout of Cpt1a results in impaired CD8+ memory T
cell generation, while retroviral Cpt1a expression promotes differentiation into memory T
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cells (van der Windt et al., 2012). Interestingly, in addition to importing fatty acids from
their extracellular environment, memory T cells can also engage in de novo fatty acid
synthesis by upregulating proteins that facilitate import of glycerol, allowing for storage
and synthesis of triglycerides that can then be broken down via FAO (Cui et al., 2015;
O’Sullivan et al., 2014). This confers memory T cells the ability to produce ATP via FAO
in conditions of nutrient stress, a feature which may have particular relevance within the
context of solid tumors, discussed further in Section 2.3. Furthermore, CD8+ memory T
cells are capable of rapidly re-activating with innate effector-like kinetics, and as they do
so, reprogram from FAO metabolism back to glycolysis (Gubser et al., 2013). This early
glycolytic switch enables them the ability to produce IFN-g, and suggests that while
memory T cell differentiation is associated with catabolic metabolism, these
differentiation states are ultimately transient and glycolysis fuels an effector response
once re-activated.
One of the most notable features of memory T cells that allows them to survive
long-term and rapidly re-activate upon secondary stimulation is their specialized
mitochondrial parameters. Upon initial antigen activation, mitochondria are cleaved from
the endoplasmic reticulum (ER) and migrate to the immune synapse to facilitate calcium
signaling that is required for proper T cell activation (Quintana et al., 2007). As these
effector cells differentiate into memory T cells, the mitochondria reorganize such that
they tightly associate with ER and become primed for sustained glucose metabolism and
enhanced IFN-g cytokine production upon secondary encounter with antigen, thus
facilitating rapid recall (Bantug et al., 2018; Rieusset, 2018).
Additionally, the mitochondria of memory T cells also undergo remodeling in their
morphology (Rambold and Pearce, 2018). Mitochondria are organized such that they
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have an outer membrane, as well as a tightly folded inner membrane designed for highly
efficient ATP production by the electron transport chain (ETC). The ETC transfers
electrons provided by reducing equivalents generated in the TCA cycle to molecular
oxygen, and as protons are pumped across a gradient, ATP is produced. In addition to
ATP production, the ETC may also produce reactive oxygen species (ROS) which can
either serve as signaling molecules or induce cellular damage (Mehta et al., 2017).
Effector T cells possess fragmented mitochondria with loose cristae (inner membrane
folds) that are actively pulled apart, and thus have reduced ETC efficiency – this is
termed mitochondrial fission and is mediated by the protein Drp1 (Baixauli et al., 2011).
In contrast, the inner mitochondrial membranes of memory T cells undergo fusion
mediated by Opa1 (Buck et al., 2016), whereby these folds are tethered together. This
enables memory T cells more efficient ETC activity, and importantly, also protects them
against DNA damage induced from accumulated ROS (Rambold et al., 2011); together,
this confers memory T cells with enhanced survival capacity particularly in conditions of
nutrient deprivation and cellular stress. Interestingly, deletion of Opa1 loosens cristae
and results in defective memory T cell generation, while effector CD8+ T cells provided
with drugs that promote mitochondrial fusion become more memory-like in phenotype
(Buck et al., 2016). However, effector T cells that lack Opa1 still have the ability to
become memory T cells, which suggests that while mitochondrial fusion and FAO are
both important for memory differentiation, they likely operate via distinct pathways to
promote T memory phenotypes.
In addition to these changes in mitochondrial morphology, memory T cells also
increase mitochondrial biogenesis. Memory T cells increase their mitochondrial mass by
upregulating the transcription factor peroxisome proliferator-activated cofactor 1α
(PGC1α), a master regulator of mitochondrial formation (Dumauthioz et al., 2020;
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Scharping et al., 2016). Together, the mitochondrial morphology and biogenesis of
memory T cells provide them with a unique, signature property: spare respiratory
capacity (SRC) (van der Windt et al., 2012). SRC is the capacity of cells to generate
reserve energy in the mitochondria, thereby allowing enhanced OXPHOS for ATP
production. This ultimately promotes greater mitochondrial health and long-term survival
– particularly in nutrient-deprived states – further supporting the ability of these cells to
retain metabolic fitness and effectively reactivate upon secondary stimulation (van der
Windt et al., 2013a). This is especially important for the ability of memory T cells to
persist within the tumor microenvironment, discussed further in Section 2.3.
The differentiation into memory T cell metabolism from effector T cells is
regulated by nutrient sensor activity. While mTORC1 is important for effector T cell
metabolic reprogramming, inhibition of mTOR activity promotes FAO catabolism and
memory T cell differentiation (Araki et al., 2009; Pollizzi et al., 2015; Rao et al., 2010).
Indeed, both rapamycin treatment and genetic knockouts of Raptor can induce memory
CD8+ T cell development (Araki et al., 2009), and furthermore, Tsc1 knockout mice (with
enhanced mTORC1 activity) show decreased memory responses in response to
bacterial infection (Shrestha et al., 2014). Another critical regulator of memory T cell
metabolic programming is adenosine monophosphate (AMP)-dependent protein kinase
(AMPK). AMPK, comprised of an α-catalytic subunit, β-regulatory subunit, and AMPbinding g-subunit, is a serine threonine kinase that is induced by TCR activation and is a
sensor of energy depletion (MacIver et al., 2011; Mayer et al., 2008; Mihaylova and
Shaw, 2011). Specifically, AMPK is activated by a high intracellular ratio of AMP:ATP
and subsequently promotes catabolic FAO metabolism to restore ATP levels within the
cell (Faubert et al., 2013; O’Neill and Hardie, 2013). AMPK and mTOR directly
antagonize one another, reciprocally acting as nutrient sensors and promoting catabolic
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and anabolic metabolic pathways respectively. Metformin – a pharmacological agonist of
AMPK activity – can induce memory T cell formation (Pearce et al., 2009), and
conversely, T cells lacking the catalytic unit of AMPK display compromised memory
formation and mitochondrial respiration (Blagih et al., 2015; Rolf et al., 2013),
demonstrating the importance of AMPK regulation of memory T cell differentiation. In
line with these observations, AMPK is also critical for promoting PGC1α expression
(Audet-Walsh et al., 2016; Jager et al., 2007; Jeninga et al., 2010), further implicating its
essential role in memory T cell formation.

Regulatory T cell (Treg) metabolism
Although the paradigm of naïve, effector, and memory T cell metabolism is relatively
well-established particularly for CD8+ T cells, CD4+ T cells have different subsets that are
functionally distinct: Th1, which produce predominantly anti-tumor cytokines, Th2, which
predominantly produce regulatory cytokines, Th17 cells which produce IL-17, and finally,
regulatory T cells (Tregs) which produce immunosuppressive cytokines. Each of these
subtypes possess unique transcriptional regulators and play different roles in disease
and responses to pathogens and tumors. As such, their metabolic demands vary as well.
A key paper by Michalek et al. established that while the three effector T cell subtypes
(Th1, Th2, and Th17) had similar profiles of predominant use of glycolysis upon
stimulation, Tregs possessed a unique metabolic profile. Tregs demonstrated high rates
of lipid oxidation, mitochondrial membrane potential, and low glycolytic activity (Michalek
et al., 2011a). Furthermore, addition of etomoxir – a pharmacological inhibitor of FAO
metabolism – resulted in impaired differentiation into Tregs in culture, and conversely,
the addition of exogenous fatty acids into media promoted Treg differentiation; this was
also enriched by AMPK activation. In line with these observations, it has also been
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shown that TGF-β drives Treg formation and activates AMPK activity (Xie et al., 2006).
Thus, Tregs display a similar metabolic profile to memory T cells, whereby upon
differentiation, AMPK promotes FAO metabolism. Importantly, the unique metabolism of
Tregs have important consequences for their adaptability to the tumor
microenvironment, particularly in conditions of hypoxia and high lactate. This is
discussed further in the next section.

2.2. Metabolic challenges within the tumor microenvironment (TME)
While the paradigm of the link between T cell metabolic properties and
differentiation states has become fairly well elucidated over the years, ultimately, the
metabolism of these cells is dynamic and dependent upon different physiological
environments, nutrient availability, and soluble and contact-mediated signals from
neighboring cells. The solid tumor microenvironment (TME) represents a particularly
challenging environment for T cells to metabolically adapt and maintain effector
functions. The solid tumor TME is comprised of diverse immune cell populations (both
pro-and anti-inflammatory), tumor cells, and stromal cells in a heterogenous and
complex matrix characterized by poor vasculature, high acidity, metabolic by-products,
and a low nutrient supply. Collectively, these conditions comprise a harsh environment
within which infiltrating lymphocytes must survive and maintain sustained functional
activity. Indeed, it is well-appreciated that the TME imposes metabolic perturbations that
result in T cell immunosuppression, impairing the ability of cytotoxic cells to exert antitumor function and effectively respond to immunotherapies (Bader et al., 2020; Rangel
Rivera et al., 2021); in contrast, immunosuppressive populations as well as tumor cells
are adapted to survive and function within these nutrient conditions, allowing for immune
evasion. Therefore, in order to design more effective immune cell-based
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immunotherapies, it is critical to dissect the mechanisms by which the metabolic
properties of tumor-infiltrating lymphocytes influence both their anti-tumor effector
functions and response to interventions within the context of the TME. In particular, our
understanding of the metabolic dynamics of T cells in the TME has become increasingly
clear in recent years, which will be the focus of this section. In contrast, very little is
known about the metabolism of NKT cells, particularly within tumor contexts – this will be
discussed more in Section 2.4.
One of the major metabolic challenges faced by T cells within the TME is
hypoxia. As the proliferation of tumor cells exceeds the ability of the vasculature to
supply oxygen, regions of hypoxia form within tumors. In hypoxic conditions, HIF1-α
expression is induced in tumor cells, allowing them to enhance glycolytic metabolism,
which results in increased secretion of lactate and continued proliferation. In tumor cells,
hypoxia is correlated with resistance to radiation therapy and evasion of cytotoxic
therapies, and additionally, it promotes VEGF-mediated angiogenesis (Augustin et al.,
2020; Brown, 1998; Hanahan and Weinberg, 2000); collectively, these mechanisms are
advantageous to tumor cell growth, yet creates poor nutrient environmental conditions
within the TME. Indeed, as T cell migrate from peripheral tissues with physiological
oxygen tension and infiltrate into solid tumors, they become subjected to increasing
hypoxia and activate HIF1-α as well; metabolically, similar to tumor cells, they also
increase glucose consumption to fuel glycolysis, as OXPHOS is limited in these
conditions (Zhang and Ertl, 2016).
The direct effects of hypoxia on effector CD8+ T cell functions have been
somewhat conflicting and not fully clear. On the one hand, in several in vitro and in vivo
studies, it has been demonstrated that hypoxia diminishes T cell activation and
expansion (Vuillefroy de Silly et al., 2016) and can inhibit production of cytokines and
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cytotoxic enzymes in T cells (Atkuri et al., 2005; Kim et al., 2008; Larbi et al., 2010;
Scharping et al., 2017). Furthermore, hypoxia can also increase the accumulation of
reactive oxygen species (ROS) within the TME, which leads to T cell apoptosis (Bell et
al., 2007; Kesarwani et al., 2013). However, other studies have also shown that in some
contexts, CD8+ T cells cultured in hypoxic conditions or with induced HIF1-α expression
actually displayed enhanced cytokine production (Doedens et al., 2013; Finlay et al.,
2012), demonstrating that hypoxia could potentially boost T cell anti-tumor immunity.
Ultimately, more studies will be needed to evaluate the mechanistic contribution of
hypoxia to effector T cells, particularly within the TME and more long-term.
Although the effects of hypoxia itself on the anti-tumor activity of T cells is not
fully clear, overall, hypoxia within the TME appears to be detrimental to T cell function
long-term by creating an unfavorable, immunosuppressive and harsh environment for
these cells through several different mechanisms (Petrova et al., 2018; Zhang and Ertl,
2016). Firstly, hypoxia increases the surface expression of the PD-L1 ligand on the
surface of both tumor cells and immunosuppressive myeloid cells (Barsoum et al., 2014;
Noman et al., 2014); PD-L1 inhibits T cell activation and signaling upon ligation by the
PD-1 inhibitory checkpoint receptor. Additionally, hypoxia can enhance the functions of
immunosuppressive cell populations within the TME. Indeed, HIF1-α expression is
correlated with an increased proportion of M2 macrophages (Ambade et al., 2016), the
subtype of macrophages that secretes immunosuppressive cytokines. Furthermore,
HIF1-α also stimulates the activity of immunosuppressive myeloid-derived suppressor
cells (MDSCs) within the TME (Corzo et al., 2010) and can upregulate further immune
checkpoints on these cells as well, including the negative checkpoint receptor V-Domain
Ig Suppressor of T-Cell Activation (VISTA) (Deng et al., 2019; Wang et al., 2018),
collectively serving to inhibit effector T cell activity. Another key immunosuppressive cell
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type influenced by hypoxic signaling is regulatory T cells (Tregs). Tregs inhibit T cell antitumor function by secreting immunosuppressive cytokines including IL-10 and TGF-β, as
well as by expressing ligands for T cell inhibitory checkpoint receptors, including CTLA-4
and LAG-3 (Vignali et al., 2008). HIF-α directly binds to the promoter region of Foxp3,
the transcription factor mediating Treg differentiation, to enhance its expression
(Clambey et al., 2012). Furthermore, hypoxic tumor cells secrete chemokines such as
CCL-17, CCL-28, and TGFβ1 that attract and promote Treg infiltration within the TME
(Hasmim et al., 2013; Li et al., 2020). Taken together, hypoxia creates favorable
conditions for both tumor cells and immunosuppressive immune cells, which in turn
dampens effector T cell activity within the TME.
Another consequence of hypoxia that also affects effector T cell metabolism and
function within the TME is enhanced acidity – specifically, high levels of lactate. As
hypoxia drives tumors to become more glycolytic, the tumor cells increasingly produce
lactate as the end product of this metabolic pathway, thereby acidifying the TME.
Indeed, it has been shown that lactate production in tumor cells can increase by 40-fold
and correlates with increased tumor size (Girgis et al., 2014; Sun et al., 2014). However,
lactate can be quite detrimental to T cell function. Specifically, tumor-derived lactic acid
inhibits IFN-g production and proliferation of T cells (and NK cells) (Brand et al., 2016;
Fischer et al., 2007; Mendler et al., 2012). Furthermore, acidity also enhances the
activity of immunosuppressive cell populations. Low pH has been shown to promote the
differentiation of monocyte-derived dendritic cells, which adapt to these conditions by
upregulating mitochondrial respiration (Erra Díaz et al., 2020). Additionally, lactate
promotes Treg survival and function within the TME, providing them with a bioenergetic
advantage in this low-glucose, high-lactate environment (Angelin et al., 2017). Tregs not
only possess the ability to effectively oxidize exogenous lactate, but intriguingly, a recent
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paper found that intratumoral Tregs actually require lactate to maintain their suppressive
functions within the TME relative to peripheral Tregs (Watson et al., 2021). This further
supports the notion that Tregs are able to metabolically adapt to the heightened lactate
and hypoxia within the TME to promote their function, while contrastingly, effector T cell
activation and functions are inhibited in these conditions long-term. As such, one way to
boost T cell immunotherapy is to identify anti-tumor effector T cells that can
metabolically adapt and function within the TME.

2.3. Relevance of immunometabolism to anti-tumor functions within the TME
The direct relevance of immunometabolism for anti-tumor activity and
persistence within the TME, as well as for the design of effective immunotherapies, has
become increasingly investigated in recent years. Many of the studies identifying the
metabolic properties of T cells in their distinct differentiation states (naïve, effector,
memory) and how they are linked to functional bioenergetic demands were performed in
vitro or in isolated conditions. However, as discussed in the previous section, the TME is
a uniquely challenging metabolic environment and as such, it is critical to understand
how the metabolic features of immune effector cells impact their long-term functionality
and survival within the TME. In addition to the challenges imposed by hypoxia,
immunosuppressive cells, and low pH within the TME, one of the major barriers to T cell
function in this environment is the competition for limited nutrients amongst tumor cells
and other immune cells. Indeed, effector T cells share many common metabolic
signaling programs and bioenergetic demands as tumor cells, and thus, these cell
populations must constantly face a nutritional “tug-of-war” within the TME (Rangel Rivera
et al., 2021).
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One of the major metabolic substrates shared by tumor cells, myeloid cells, and
immune effector cells including T cells is glucose. As discussed in Section 2.2, effector T
cells become highly glycolytic upon activation to support their anti-tumor functions, while
tumor cells are also very glycolytic, as both populations engage Warburg metabolism,
and thus must compete for glucose availability. Intriguingly, in a study that directly
measured glucose uptake and glycolysis in activated T cells and leukemic T cells, it was
discovered that the activated T cells actually have a significantly higher rate of glycolysis
metabolism (Kishton et al., 2016) – this implies that even though activated T cells have
the potential for higher glycolysis than tumor cells, they are highly inhibited within the
TME, where they face competition for glucose from tumor cells that dominate the TME,
as well as accumulated waste products, hypoxia, and acidity from tumor cells and
immunosuppressive cells. Indeed, as mentioned in Section 2.2, glucose deprivation in
vitro impairs T cell effector functions, including proliferation, cytokine production, and
cytotoxicity. However, in addition, several studies sought to directly investigate direct
nutrient competition between T cells and tumor cells within the TME and investigate how
this affects tumor progression.
One example is in renal cell carcinoma, where Glut1 expression on tumor cells
was found to be inversely correlated to the infiltration and cytotoxic capacity of CD8+ T
cells (Singer et al., 2011). Furthermore, two key papers in 2015 importantly
demonstrated the functional importance of direct competition for glucose within the TME.
In the first, the Pearce group found in a xenograft sarcoma model that increasing tumor
cell glycolytic capacity enhanced tumor progression and resulted in lower infiltrating T
cell glucose consumption, IFN-g secretion, and proliferation; however, this could be
rescued by addition of glucose ex vivo in co-culture studies, and when these higherglycolytic T cells were re-injected into tumors, they displayed better anti-tumor function
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and this resulted in improved tumor regression (Chang et al., 2015). Indeed, this
demonstrated the direct tug-of-war of glucose between tumor cells and T cells and the
opposing roles that the glucose metabolism of these cells plays in directly impacting
tumor progression. The second paper from 2015 by the Kaech group utilized a
melanoma murine xenograft model and showed that tumor-filtrating T cells with
enhanced glycolysis (by overexpression of glycolytic enzyme expression) displayed
bolstered effector functions and in turn, resulted in restricted melanoma growth in vivo,
providing T cells with a metabolic advantage (Ho et al., 2015). Although in the contexts
of these two papers, glycolysis was an advantage to the effector T cells for performing
anti-tumor functions, it is very possible that either long-term and/or in a true TME context
(i.e. not in an artificial xenograft model), they would eventually succumb to exhaustion or
cell death. Nevertheless, these studies importantly demonstrated the requirement of
glucose for both tumor cells and T cells, and how the competition for glucose can impact
tumor progression beyond simply altering their in vitro functionality individually.
Together, these studies also more broadly demonstrate the importance of immune cell
metabolism for influencing tumor growth.
One of the key metabolic challenges faced by T cells that infiltrate solid tumors is
the ability to withstand the nutrient competition and harsh conditions of the TME to
survive and sustain anti-tumor functions. Indeed, to persist long-term within the solid
TME, several studies have demonstrated the critical importance of memory-like
mitochondrial metabolism and the FAO pathway. One study investigated tumor
infiltrating T cells relative to peripheral T cells in both a murine B16 melanoma tumor
model as well as tumors from human head and neck squamous cell carcinoma (HNSCC)
patients. Interestingly, they found that the intratumoral T cells specifically had lower
mitochondrial mass and depolarization, and that this mitochondrial dysfunction was
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associated with upregulation of inhibitory checkpoint receptors including PD-1, LAG-3,
and Tim-3 (Scharping et al., 2016). Mechanistically, these observations were due to
downregulated expression of PGC1-α (which regulates mitochondrial biogenesis) and
chronic Akt activity. Importantly, when PGC1-α was retrovirally overexpressed in T cells,
these cells had higher mitochondrial mass, OXPHOS metabolic activity, and greater
spare respiratory capacity that resulted in significantly improved survival of tumorbearing mice. These findings suggest the direct importance of mitochondrial biogenesis
and fitness for anti-tumor function of T cells within the TME and may also have key
therapeutic implications for the design of more effective T-cell based immunotherapies
that harness these metabolic features.
In line with these findings, another group found that CD8+ T cells within clear cell
renal cell carcinoma (ccRCC) primary patient tumors, although abundant in frequency,
displayed metabolic deficiencies and altered mitochondrial morphology relative to T cells
in the spleens of matched patients. Specifically, the intratumoral T cells were unable to
efficiently uptake glucose, possessed smaller, fragmented, hyperpolarized mitochondria,
and greater accumulation of reactive oxygen species (ROS) (Siska et al., 2017).
Importantly, these features were all associated with impaired activation and proliferation
of the T cells within tumors, and were rescued by supplementation of pyruvate and
compounds that scavenge mitochondrial ROS. This study further demonstrated the link
between metabolic and functional impairment in T cells within the TME, and specifically
highlighted the importance of intact mitochondria for the health and integrity of T cells in
this environment. These findings corroborate that of Scharping et al. and suggest ways
by which to improve both the quality and longevity of T cells and preserve their antitumor functions in solid tumors long-term; this will be discussed further in Chapter 4.
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Finally, the importance of TME conditions promoting T cell mitochondrial
metabolism – specifically fatty acid catabolism – was demonstrated in a melanoma solid
tumor model. Specifically, Zhang et al. (2017) discovered that tumor-infiltrating CD8+ T
cells experienced metabolic stress and exhaustion that increased over time. As tumor
progression ensued, these intratumoral T cells induced expression of peroxisomal
proliferator-activated receptor-α (PPAR-α) a transcription factor that promotes
breakdown and uptake of fatty acids, as well as Cpt1a, the rate-limiting enzyme of FAO,
relative to splenic CD8+ T cells. This enabled the intratumoral T cells to induce fatty acid
catabolism, enabling them to preserve energy production and maintain effector functions
within the TME. In this model, the fatty acid metabolism of the intratumoral T cells
directly influenced tumor progression and response to checkpoint blockade therapy, as a
PPAR-α agonist demonstrated clinical efficacy in delaying tumor growth (Zhang et al.,
2017). These findings further emphasize the importance of memory-like, non-glycolytic
metabolism on preserving the anti-tumor functions of T cells long-term within the TME.
Taken together, these studies collectively demonstrate the critical link between
metabolism and anti-tumor activity of T cells within the TME, and importantly, how these
metabolic properties of infiltrating immune effector cells can directly influence tumor
progression. This underscores the need to better understand the metabolism of immune
effector cells in order to better harness their anti-tumor activity for clinical benefit.

2.4. NKT cell metabolism
As described in the previous sections, the metabolic features of conventional T
cells (TCONV) have become increasingly elucidated over the years – from correlating
basic in vitro metabolic properties and bioenergetic demands to function in naïve,
effector, and memory differentiation states, to investigating T cell metabolism within solid
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tumor models and correlating this to tumor progression. In contrast, very little is known
about the metabolism of iNKT cells. Only a small handful of studies have investigated
iNKT cell metabolic properties, and to date, we have a very limited understanding of their
basic metabolic features at baseline, upon stimulation, and within the context of the
TME.
A few studies have begun to elucidate the link between iNKT cell metabolism and
thymic development and maturation. The mTOR nutrient sensor protein complexes have
been demonstrated to play important roles in iNKT cell development. Mice with T-cell
specific deletion of either Raptor or Rictor (components of mTORC1 and mTORC2,
respectively) exhibit inhibited iNKT cell development, with an accumulation of thymic
iNKT cells at stage 0 and 1 and decreased stage 2 and 3 iNKT cells (Prevot et al., 2015;
Shin et al., 2014; Zhang et al., 2014). Furthermore, Raptor-deficient iNKT cells have
reduced nuclear localization of PLZF (Shin et al., 2014), and PLZF itself can control
mTORC1 signaling (Yang et al., 2015). While these studies have not specifically
examined the metabolic parameters of developing iNKT cells, given the importance of
mTOR signaling in nutrient sensing, the findings may indicate a potential link between
immunometabolic features associated with the intra-thymic maturation of iNKT cells and
how these features may mechanistically differ from TCONV.
Additionally, it has been shown that mitochondrial ROS and the ETC may have
important roles in iNKT cell development that are unique from TCONV. ROS are
byproducts of aerobic metabolism that mediate redox biology and oxidative stress; in
some contexts, ROS act as important second messengers for immune cell signaling
(and indeed, are increased in T cells upon activation), but at high levels, can induce
oxidative stress and cell and tissue damage. It was observed that PLZF (the
transcriptional regulator of iNKT cell differentiation) controls ROS levels in murine iNKT
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cells, and indeed, splenic and hepatic iNKT cells had significantly higher levels of ROS
relative to TCONV; these ROS levels correlated with production of IFN-g cytokine upon
stimulation specifically in iNKT cells (Kim et al., 2017). These data suggest a potential
difference in metabolic signaling in iNKT cells relative to TCONV that may not only impact
effector functions but also susceptibility to oxidative stress.
In line with these observations, a recent paper investigated the dependency on
mitochondrial metabolism for the development and effector functions of iNKT cells
relative to TCONV (Weng et al., 2021). Interestingly, they found that at baseline, splenic
murine iNKT cells and CD4+ T cells had comparable rates of oxygen consumption, yet
iNKT cells displayed lower spare respiratory capacity (SRC), as well as lower
mitochondrial mass and mitochondrial membrane potential. To understand the role of
mitochondrial metabolism for the thymic development of these cells, Weng et al. utilized
mice with T-cell specific deletion of RISP (Uqcrfs1-/-), a subunit of mitochondrial complex
III, which effectively inhibits mitochondrial ATP production as well as ROS production.
Compared to wild-type mice, iNKT cell frequencies within the thymus were dramatically
reduced with RISP ablation, and additionally, iNKT cell maturation was greatly
diminished. Furthermore, inhibition of mitochondrial ATP and ROS production led to
increased apoptosis and impaired TCR signal responsiveness in thymic iNKT cells, and
also diminished the ability of iNKT cells to respond to stimulation in vitro – characterized
by reduced cytokine production and expression of the activation marker CD69 (Weng et
al., 2021). Together, these data suggest a unique dependency on mitochondrial
metabolism by iNKT cells for development and effector functions that may be distinct
from TCONV. Although it is still not fully clear how mitochondrial dynamics affect mature
iNKT cell stimulation-induced effector functions, this data implies that iNKT cells may
have unique mitochondrial features from TCONV that could potentially underlie their
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effector-memory phenotype and have important consequences for anti-tumor functions
as well.
In addition to the link between metabolic parameters and iNKT cell development,
a few studies have begun to investigate the immunometabolism of iNKT cells in the
context of fueling effector functions or adapting to TME conditions. To date, the studies
that were performed have primarily investigated murine, splenic iNKT cells and
compared these to CD4+ conventional T cells. Shin et al. examined the role of mTOR on
iNKT cell effector functions, and found that rapamycin-mediated inhibition of mTORC1
resulted in impaired α-GalCer-induced murine iNKT cell proliferation and production of
IFN-g, IL-4, and TNF-α cytokines (Shin et al., 2014). This implies that metabolic
pathways regulated by mTOR play important roles in directly influencing iNKT cell
function, though further metabolic characterization is warranted.
In 2019, two papers investigated iNKT cell metabolism at baseline relative to
stimulation. In the first, it was found that immunometabolism plays a role in TCR
recycling upon acute activation of mouse iNKT cells, and in turn regulated IFN-g
production. Specifically, this group sorted splenic and hepatic iNKT cells with an
activated CD44+CD62L- phenotype and stimulated them in vitro with CD3 and CD28 with
or without inhibition of glycolysis via the inhibitor 2-DG. They found that inhibition of
glucose metabolism reduced the ability of iNKT cells to proliferate and secrete IFN-g,
polarizing them to a more Th2 cytokine response – and furthermore, that this inhibited
the process of iNKT cells recycling their TCR upon activation (Fu et al., 2019). Notably,
this event of TCR recycling occurs relatively shortly upon activation, within 45-90
minutes. Thus, this data suggests that glycolysis may play an important role for early
activation of this particular subset of mouse iNKT cells, but more thorough
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characterization of different time points and direct comparisons to TCONV would still be
needed to establish how glycolysis regulates iNKT cell effector functions.
In the next paper, Kumar et al. investigated the metabolic and effector properties
of baseline and stimulated murine, splenic bulk iNKT cells relative to CD4+ TCONV and
found several distinct immunometabolic properties between the two cell types; notably,
for all studies comparing rest vs. 72-hour stimulation, iNKT cells were stimulated with αGalCer, while T cells received anti-CD3+28 stimulation, so while both stimulate TCR
signaling, they were not equally matched conditions. Nevertheless, they observe that
iNKT cells uptake less glucose than CD4+ T cells upon stimulation, and iNKT cells were
less sensitive to glucose depletion for proliferation than TCONV (Kumar et al., 2019). Upon
stimulation in decreasing glucose concentrations, iNKT cells did display a dosedependent decrease in production of IFN-g, IL-4, and IL-17 cytokines, yet were more
sensitive to inhibition of OXPHOS for proliferation and survival, indicated by studies
treating these with oligomycin A (an ATP synthase inhibitor that blocks ATP production
via OXPHOS). In line with greater use of oxidative metabolism, iNKT cells also had
higher mitochondrial mass and membrane potential at baseline relative to TCONV (though
both equally upregulated these upon stimulation), and furthermore, demonstrated higher
mRNA expression of TCA cycle genes upon stimulation relative to stimulated TCONV
(Kumar et al., 2019). Interestingly, stimulated iNKT cells also had higher expression of
pentose phosphate pathway (PPP) genes than TCONV as well as higher intracellular ATP
levels yet lower intracellular lactate, indicating that perhaps they utilize glucose
predominantly for PPP metabolism and the TCA cycle and OXPHOS downstream of
glycolysis rather than producing lactate – to assess this more carefully, glucose tracing
studies would be needed. They also did not look at cytotoxicity, so the metabolic
requirements for this particular effector function remain unclear. Regardless, their data
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suggests that iNKT cells display unique metabolic features from CD4+ TCONV and
underscores the importance of OXPHOS metabolism for iNKT cells in in vitro conditions.
Finally, another recent paper investigated lipid biosynthesis in both peripheral
and intratumoral iNKT cells, importantly investigating iNKT cell immunometabolism
within a tumor context for the first time. Murine splenic iNKT cells were shown to express
higher levels of PPAR-g, a regulator of lipid biosynthesis, relative to conventional CD4+
and CD8+ T cells (Fu et al., 2020a). Indeed, iNKT cells engaged PPAR-g-dependent lipid
biosynthesis upon CD3 and CD28 stimulation that was required for production of Th1
cytokines including IFN-g, IL-2, and TNF-α by a mechanism involving PLZF-mediation
transcription of Srebf1 (sterol regulatory element-binding protein 1), a transcription factor
that regulates the biosynthesis of lipids. Importantly, in B16F10 melanoma xenograft
tumors, tumor-infiltrating iNKT cells displayed reduced PPAR-g levels, SREBP1, and
cholesterol levels, as well as lower IFN-g levels than splenic iNKT cells in these mice;
however, upon treatment with pioglitazone (PIO) – a drug that activates PPAR-g – the
IFN-g production and lipid synthesis was somewhat restored and resulted in better antitumor efficacy, lowering tumor size and improving survival of tumor-bearing animals (Fu
et al., 2020a). Importantly, they also found similar patterns of PPAR-g and SREBP1
expression (and correlation to IFN-g) in intratumoral iNKT cells from human
hepatocellular carcinoma (HCC) patient samples – however, how lipid biosynthesis
promotes IFN-g within the TME is still somewhat unclear in human iNKT cells, as these
were cultured ex vivo from tumors for several hours. Nevertheless, these findings
demonstrate for the first time the importance of lipid metabolism for the anti-tumor
cytokine production of stimulated iNKT cells that may have important translational
relevance.
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Ultimately, there still remains a great need for better understanding human iNKT
cell metabolism, particularly side-by-side relative to TCONV (Figure 2.1). To address this
gap in the field of iNKT immunometabolism, we investigated the bioenergetic demands
of human iNKT cells and their link to anti-tumor effector functions relative to TCONV in
Chapter 3. Furthermore, a discussion of how our novel findings on human iNKT cell
metabolism is relevant to the design of future iNKT cell-based immunotherapies is
addressed in Chapter 4.
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2.5. Figures

Figure 2.1. Summary of human TCONV and iNKT cell immunometabolism and link to effector
functions. This thesis work is focused on better identifying the metabolic pathways required for
iNKT cell anti-tumor cytokine production and cytotoxicity (right) relative to TCONV (left).

48

CHAPTER 3: DISTINCT BIOENERGETIC REQUIREMENTS OF HUMAN INVARIANT
NATURAL KILLER T (iNKT) CELLS ENABLE RETAINED EFFECTOR FUNCTIONS
IN NUTRIENT-DEPRIVED STATES
Parts of this chapter were previously submitted for publication as follows:
Priya Khurana, Chakkapong Burudpakdee, Stephan A. Grupp, Ulf H. Beier, David M. Barrett,
and Hamid Bassiri. Distinct bioenergetic requirements of human invariant natural killer T (iNKT)
cells enable retained effector functions in nutrient-deprived states (2021). In Press and available
as a pre-print on BioRxiv: (https://doi.org/10.1101/2021.04.29.442021)

3.1. Introduction
Invariant natural killer T (iNKT) cells comprise a subset of innate-like T
lymphocytes with TCR specificity for glycolipid antigens presented by the monomorphic,
MHC I-like molecule CD1d (Bendelac et al., 2007b). iNKT cells possess innate-like
effector cell features, including rapid activation, cytokine secretion, and trafficking to
tumor sites; as such, iNKT cells bridge innate and adaptive immune responses (Brennan
et al., 2013; Matsuda et al., 2008). The presence of both circulating and intratumoral
iNKT cells predicts more favorable tumor prognosis and survival in patients with several
solid and liquid tumors (reviewed in (Wolf et al., 2018)), suggesting that these cells play
central roles in cancer immunity. This notion is supported by a body of literature
(reviewed in (Altman et al., 2015)) that demonstrate that iNKT cells engage in both direct
anti-tumor cytotoxicity against CD1d-expressing tumors (Bassiri et al., 2014; Kawano et
al., 1997) and modulate the activity of many other immune cells, including natural killer
(NK) cells, CD8+ T cells (Carnaud et al., 1999; Crowe et al., 2002; Iyoda et al., 2018;
Metelitsa et al., 2001; Mise et al., 2016; Smyth et al., 2002), and myeloid cells (Kitamura
et al., 1999; Mussai et al., 2012; Song et al., 2009).
Recently, iNKT cells have begun to be utilized as a platform for cellular
immunotherapy, as either adoptively-transferred cells (Exley et al., 2017; Kunii et al.,
2009; Yamasaki et al., 2011b) or chimeric antigen receptor (CAR)-transduced effectors
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directed against tumor antigens in lymphoma and solid tumor models (Heczey et al.,
2014; Rotolo et al., 2018). While the studies published to date have demonstrated some
efficacy, these trials are in early clinical stages and very little is understood about the
basic cellular properties of iNKT cells that govern their ability to adapt to the tumor
microenvironment (TME). Thus, there is a great need to better understand the metabolic
properties of these cells in order to better inform the design of iNKT cell-based solid
tumor immunotherapies in the future, particularly those that challenge existing
conventional T cell (TCONV)-based therapies.
In TCONV, cellular metabolism is tightly linked to effector functions. Upon TCR
stimulation, TCONV undergo metabolic reprogramming as they differentiate from naïve to
effector states, shifting from predominant use of oxidative phosphorylation (OXPHOS) to
a preferential reliance on glycolysis and glutaminolysis to fuel substrate biogenesis and
effector functions (Pearce et al., 2013). In the TME, the long-term functional capacity of
TCONV is minimized as they compete with tumor cells and tumor-supporting myeloid cells
for limited glucose and glutamine (Chang et al., 2015; Ho et al., 2015). In contrast,
memory T cells, which predominantly utilize fatty acid oxidation (FAO), are more
persistent within the TME (Buck et al., 2016; Scharping et al., 2016; Sukumar et al.,
2013). In addition, regulatory T cells (TREG) rely on OXPHOS and FAO (Michalek et al.,
2011b), allowing them to maintain immunosuppressive functions within the TME. Given
that the metabolic profiles of TCONV and other immune cells have been demonstrated to
directly influence tumor progression, the use of therapies that modulate TME metabolism
represent attractive treatment options for solid tumors.
In contrast to TCONV, however, little is known about iNKT cell metabolism and its
link to key anti-tumor effector functions such as cytokine production and cytotoxicity.
Unlike TCONV, iNKT cells do not have distinct differentiation states and exit the thymus
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primed for activation (D’Andrea et al., 2000); these functional differences may indicate a
unique underlying metabolic phenotype. Indeed, murine iNKT cells have been
demonstrated to depend predominantly on OXPHOS for survival (Kumar et al., 2019)
and have also been shown to increase lipid biosynthesis upon activation, both in vitro
and within the TME (Fu et al., 2020b). Together, these data suggest that murine iNKT
cells may have different bioenergetic profiles from TCONV, which could have significant
consequences for their survival and function within the TME. While these studies have
begun to elucidate the metabolic profiles of murine iNKT cells, a metabolic
characterization of human peripheral blood iNKT cells and how it is linked to anti-tumor
effector functions relative to TCONV has not been determined previously.
In this study, we sought to delineate the metabolic and functional properties of
rested and stimulated human iNKT cells relative to TCONV under both normal and
nutrient-deplete conditions. Using peripheral blood-derived iNKT cells and matched
TCONV from healthy human donors, we demonstrate distinct bioenergetic requirements
between iNKT cells and TCONV for cytokine production and cytotoxicity after TCR
stimulation. Specifically, we demonstrate that iNKT cells maintain effector functions in
glucose- and glutamine-depleted conditions, and furthermore, utilize FAO metabolism to
a greater extent than do TCONV. Our findings not only unveil novel bioenergetic features
of primary human iNKT cells, but also suggest that iNKT cells may possess enhanced
adaptability and longevity within the TME. Importantly, these features could be co-opted
in the design of future iNKT cell-based solid tumor immunotherapies.

3.2 Results
Optimizing the expansion and stimulation of primary human iNKT cells in culture.
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Given that the frequency of invariant natural killer T (iNKT) cells in peripheral
blood is only <0.5% in most human donors, it was essential to expand this population to
obtain sufficient numbers of cells to utilize for our metabolic and functional studies.
Indeed, given this low frequency, most iNKT cell studies to date have focused on murine
cells and thus very little information is known about the basic cellular and metabolic
properties specifically of human iNKT cells. To overcome this barrier and reliably obtain
sufficient cell numbers, we utilized a protocol to expand iNKT cells from bulk peripheral
blood mononuclear cells (PBMC) from healthy human donors obtained from the
University of Pennsylvania Human Immunology Core (previously described in (Das et
al., 2013)). Briefly, bulk PBMCs were plated in media containing alphagalactosylceramide and IL-2, followed by addition of IL-15 on day 3-4 of expansion,
yielding 1-40% iNKT cells by day 7 of expansion (see methods section in 3.4 for more
detail).
To characterize the metabolic profile of iNKT cells and understand its link to
effector functions, we aimed to 1. characterize the metabolism of both baseline iNKT
cells and stimulated iNKT cells in order to assess whether there is any reprogramming
upon stimulation akin to what has been described for conventional T cells (TCONV), and 2.
directly compare iNKT cell metabolism to that of TCONV, which could not only act as
known controls, but could also be used to establish a comparison of relative metabolic
differences or similarities between the two cell types. To achieve the first goal, we
sought to optimize the best way to “rest” the iNKT cells, as they become activated during
the course of the 7-day expansion. To determine the best duration of rest for these
expanded cells (i.e. time needed to return to a more baseline activation state), we
harvested FACS-sorted iNKT cells immediately post-sort (day 8) or rested these sorted
iNKT cells in culture for different time points (24 hours, 48 hours, and 72 hours), after
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which they were harvested for RNA. Using Ifng mRNA expression as an indicator of
iNKT cell activation by which to assess if they were “rested”, we profiled these cells by
qPCR and as expected, with longer periods of rest time, iNKT cell Ifng mRNA
expression gradually declined from the expression level post-expansion (Figure 3.1A).
Furthermore, we tested different types of stimulation post-expansion to see which
induced the highest levels of Ifng induction relative to expanded iNKT cells and 48-hour
rested iNKT cells. When comparing two different ratios of anti-CD3/CD28 Dynabeads to
α-GalCer, IL-2, and IL-15 (at the same concentrations as expansion, for 48 hours of
“continued” expansion after sorting), we observed that the CD3/CD28 Dynabeads induce
the highest Ifng mRNA in iNKT cells (Figure 3.1B). To achieve the second goal of
directly comparing iNKT cells to TCONV side-by-side, we obtained matching human donor
TCONV for all of our metabolic studies. The specific cell subsets profiled and stimulations
utilized are discussed in the next section.

Human iNKT cells and TCONV display differential metabolic gene expression.
To investigate whether human iNKT cells have different metabolic profiles from
TCONV, we initially FACS-sorted three subsets of iNKT cells (CD4+, DN, and CD8+) and
harvested cells for RNA immediately post-sort after expansion. In parallel, we obtained
purified, healthy donor-derived CD4+ and CD8+ T cells and either harvested unstimulated
cells or we stimulated these cells with a 3:1 ratio of anti-CD3/CD28 Dynabeads for 48
hours (this ratio and time point had been previously optimized by Dr. David Barrett’s
laboratory to use for metabolic transcriptional studies in T cells). To get a broad survey
of metabolic gene expression in these different cell subsets, we utilized NanoString
nCounter transcriptional profiling for targeted gene expression analysis using the
NanoString SPRINT machine. We first used the NanoString RNA Vantage Cancer
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Metabolism probe set, which contains ~200 probes for genes in different metabolic
pathways. Our findings revealed that expanded iNKT cells possessed different
expression patterns of metabolic enzyme transcripts relative to unstimulated and
stimulated TCONV. Specifically, expanded iNKT cells displayed significantly lower
expression of glycolytic gene expression than stimulated CD4+ and CD8+ TCONV (Figure
3.2A), yet higher expression of several hypoxia-related genes (Figure 3.2B) and
differential patterns of mTOR signaling gene expression (Figure 3.2C). Importantly,
these metabolic differences between the cell types did not appear to be explained by the
extent to which each cell type was stimulated, as the expression levels of most activation
genes profiled were similar in both iNKT cells and TCONV (Figure 3.2D). Additionally,
these assays revealed similar expression of the metabolic genes in our NanoString
probe set between CD4+ and CD8+ T cells. Given that TCONV were predominantly being
used as controls (given that prior publications have documented the metabolic shifts of
TCONV subsets), we decided that all future experiments would use a 1:1 mixture of CD4+
and CD8+ T cells. As such, hitherto fore “TCONV” refers to these 1:1 mixtures of CD4+ and
CD8+ human T cells.
Furthermore, although this data preliminarily suggested that iNKT cells may
possess distinct metabolic features from TCONV, we had not been subjecting the cell
types to identical stimulation conditions. In this case, the iNKT cells were stimulated with
α-GalCer, IL-2, and IL-15 for 7-10 days while the TCONV were stimulated with antiCD3/CD28 microbeads for 48 hours; although both of these methods stimulate cells via
the TCR, to more accurately compare the metabolic and functional properties of these
cells equally, we sought to subject them to identical stimulation methods for an equal
duration of time. Since we had observed that at 48 hours, iNKT cells were sufficiently
rested – measured by a decrease in Ifng mRNA expression significantly below that of
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expanded iNKT cells, close to zero (per Figure 3.1), we opted to rest and stimulate
matched, sorted iNKT cells and TCONV for 48 hours using a 2:1 bead ratio of antiCD3/CD28 Dynabeads. This bead ratio enables adequate stimulation of both cell types
and also still preserves some iNKT cell viability, as iNKT cell viability was sensitive to
excess bead stimulation (data not shown). Furthermore, we opted to profile bulk
expanded PBMC-derived iNKT cells, as subsetting these cells into CD4+, CD8+ and DN
populations would limit our capability to perform studies requiring larger numbers of
cells. Thus for all subsequent studies, we used this expansion scheme to compare the
metabolic and functional features in four different cell populations: unstimulated TCONV
(48 hours in low-dose IL-2), stimulated TCONV (48 hours in 2:1 Dynabeads), rested iNKT
cells (post-expansion, 48 hours in low-dose IL-2), and stimulated iNKT cells (postexpansion, 48 hours in 2:1 Dynabeads). Although the iNKT cells receive prior expansion,
we believe that “resetting” the rest and stimulations to identical conditions was the best
possible way to equally compare these cell types. This full expansion and stimulation
scheme is depicted in Figure 3.3.

Human iNKT cells maintain anti-tumor effector functions in glucose-depleted culture
conditions relative to TCONV.
To better understand the bioenergetic requirements of human iNKT cells and
investigate whether these features are unique from TCONV, we first investigated the
dependency of these cells on glucose for anti-tumor cytokine production and cytotoxicity.
Glucose is a limited nutrient within the TME and is rapidly metabolized by highly
glycolytic tumor cells. Indeed, several prior studies have demonstrated that in vitro
glucose depletion impairs the effector functions of TCONV (Cham and Gajewski, 2005;
Cham et al., 2008; Chang et al., 2013) and that reliance on glycolysis confers poorer
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persistence and survival within the tumor microenvironment (TME) (Bengsch et al.,
2016; Scharping et al., 2016). A recent study suggested that mouse iNKT cells uptake
less glucose than CD4+ T cells (Kumar et al., 2019), suggesting that they may be less
reliant on glucose metabolism. To assess the requirement of glucose for human iNKT
cell effector functions, iNKT cells and TCONV were rested or stimulated in culture
conditions containing either standard glucose (10mM) or depleted glucose (1mM or
0.1mM) concentrations for 48 hours. Intriguingly, iNKT cells were able to maintain levels
of both Ifng mRNA and secreted IFN-g upon stimulation in low glucose media (Figure
3.4A-D). In contrast, TCONV were sensitive to glucose depletion and demonstrated a
dose-dependent decrease in Ifng transcripts and IFN-g secreted protein levels. Strikingly,
in 0.1mM glucose conditions, TCONV displayed an 85% reduction in stimulation-induced
Ifng mRNA and an over 70% reduction in IFN-g protein secretion relative to 10mM
glucose, while iNKT cells had no significant changes in IFN-g levels (Figure 3.4D). In
addition to IFN-g secretion, we also observed a similar trend in the secretion of additional
cytokines, including TNF-α and IL-4 (Figure 3.5), whereby iNKT cells did not rely on
glucose for stimulation-induced secretion of these cytokines while TCONV demonstrated
dose-dependent decreases in TNF-α and IL-4 secretion with reduced glucose. In order
to ensure that these observations in differences in fold change Ifng mRNA and protein
were not to differences in the baseline, rested population levels in glucose-depleted
media, we also quantified Ifng in unstimulated TCONV and rested iNKT cells, and did not
observe any significant differences upon culture in the glucose-deplete media conditions
(Figure 3.6) – thus, we can conclude that while glucose depletion specifically affects
stimulated TCONV, it does not alter the cytokine production of stimulated iNKT cells.
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We next investigated the dependency of these cells on glucose for cytotoxicity by
measuring levels of intracellular granzyme B, a surrogate for anti-tumor cytotoxic granule
exocytosis. We found that stimulated iNKT cells maintain similar levels of intracellular
granzyme B in glucose-deplete conditions, whereas TCONV consistently displayed a
significant reduction in granzyme B levels upon stimulation in lowered glucose
concentrations (Figure 3.4E). Indeed, in 0.1mM glucose conditions, stimulated TCONV
granzyme B levels were reduced by approximately 85% relative to 10mM glucose, while
stimulated iNKT cells displayed no significant difference in granzyme B with reduced
glucose (Figure 3.4F). To ensure that these effects were not due to a difference in cell
viability in glucose-depleted conditions in each cell type, we quantified the viability of
iNKT cells and TCONV and did not observe any significant differences in either cell type
cultured in low glucose (Figure 3.7), indicating that glucose metabolism is not essential
for the survival of either population.
As an additional approach, we also treated iNKT cells and TCONV with 2-deoxy-Dglucose (2-DG), a synthetic glucose analog that inhibits downstream glucose
metabolism (Pajak et al., 2020). Although at a higher concentration of 2-DG (20mM), the
effector functions of both iNKT cells and TCONV were impaired, iNKT cells still retained
some level of IFN-g production; however, at a lower concentration of 2-DG (2 mM), iNKT
cells actually displayed moderately higher levels of cytokine production and cytotoxicity
than in untreated conditions, while TCONV were sensitive to glycolytic inhibition (Figure
3.8). Collectively, these data further support the notion that iNKT cells are less glucosedependent for effector functions than TCONV and likely utilize alternate metabolic
pathways upon stimulation.

Human iNKT cells are less glycolytic than TCONV.
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The striking differences in the sensitivity of iNKT cells and TCONV to glucose
depletion suggest a potential underlying difference in glycolytic metabolism. While TCONV
upregulate glycolysis upon stimulation, the metabolic activity of human iNKT cells is
unknown. Using a NanoString probe set with over 700 curated transcripts for genes
involved in cancer immunology and metabolism, we assayed changes in the mRNA
expression of metabolic genes in rested and stimulated PBMC-derived iNKT cells and
matched TCONV from 8 independent donors. In contrast to TCONV, which upregulated
glycolytic pathway enzyme transcripts upon stimulation, iNKT cells only upregulated a
small subset of the glycolytic genes upon stimulation, and to a lesser extent than TCONV
(Figure 3.9A). Indeed, of the 13 glycolytic genes probed, 8 were significantly
differentially expressed between stimulated TCONV and stimulated iNKT cells, and of
these 8 genes, 7 were significantly higher in TCONV: Hk2, Ldha, Ldhb, Aldoa, Eno1,
Gapdh, and Pdha1 (Figure 3.9B and Table 1). Each of these genes encode key
enzymes throughout the glycolysis pathway that also fuel additional biosynthetic
pathways.
In TCONV, the transcription factor Myc is a master regulator required for initiation
and maintenance of glycolytic metabolic reprogramming after TCR stimulation (Wang et
al., 2011). In iNKT cells, the role of Myc, particularly upon activation, has not been
previously examined. Consistent with reduced glycolytic reprogramming in stimulated
iNKT cells, we also found that iNKT cells have significantly lower upregulation of Myc
pathway genes than stimulated TCONV (Figure 3.10 and Table 2). This difference in
transcription of genes downstream of Myc signaling could suggest a mechanistic
difference in the metabolic regulation of these two cell types.
Together, both the glycolysis and Myc pathway gene expression data suggest
that human iNKT cells, in comparison to TCONV, employ distinct metabolic pathways from
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TCONV upon TCR stimulation. Importantly, iNKT cells’ lack of dependence on glycolysis
could be advantageous in the context of the TME, whereby iNKT cells may be able to
maintain superior anti-tumor effector functions in glucose-diminished conditions in which
TCONV are at a disadvantage.

Human iNKT cells are less sensitive to glutamine depletion than TCONV for maintaining
effector functions.
Given that stimulated human iNKT cells were not dependent on glucose
metabolism for effector functions, we wondered if they instead utilize glutamine as an
alternative metabolic substrate to fuel cytokine production and cytotoxicity. Through
glutaminolysis, glutamine is metabolized into α-ketoglutarate, which directly enters the
TCA cycle to eventually yield ATP via oxidative phosphorylation (OXPHOS). Upon TCR
activation, TCONV increase both glutamine and glucose uptake and metabolism in order to
fuel effector functions (Carr et al., 2010; Nakaya et al., 2014b; Wang et al., 2011). In
contrast, the role of glutamine has not yet been elucidated in iNKT cells.
To investigate whether glutamine is required for iNKT cell effector functions, we
rested and stimulated matched human iNKT and TCONV in either complete or glutaminefree media using the schema described in Figure 3.3. Upon stimulation in glutaminedeplete conditions, iNKT cells display a moderate decrease in Ifng mRNA expression of
~40% of those stimulated in complete media, while TCONV reduced stimulation-induced
Ifng mRNA expression by ~60% in glutamine-free conditions relative to complete media
(Figure 3.11A-B). Strikingly, IFN-g secretion was not altered in iNKT cells stimulated in
the absence of glutamine, whereas it was reduced by ~90% in TCONV (Figure 3.11C-D).
These data imply a differential reliance on glutamine for cytokine production between
these cell types. We also observed preserved secretion of additional cytokines (TNF-α
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and IL-4) by iNKT cells stimulated in glutamine-deplete conditions (Figure 3.12). Similar
to with the glucose depletion, we also tested whether glutamine depletion only affects
the stimulated cells or whether there was any difference in unstimulated TCONV and
rested iNKT cells that accounted for the differences in fold-change Ifng mRNA and
protein that we observe upon stimulation. Although glutamine depletion slightly lowered
Ifng mRNA and protein secretion in resting iNKT cells, this was not statistically
significant, and unstimulated TCONV similarly did not show differences in Ifng in glutaminefree media (Figure 3.13). Once again, this confirms that the differences in functional
capacity that we observe in TCONV and iNKT cells in glutamine-depleted conditions
specifically affects the stimulated cell populations. Furthermore, while glutamine
depletion almost entirely abrogated TCONV intracellular granzyme B levels, iNKT cells
were able to retain some granzyme B production even when stimulated in the absence
of glutamine – measuring ~65% of that of levels in normal conditions (Figure 3.11E-F).
Thus, this indicates that unlike TCONV, glutamine is also not required for iNKT cell
cytotoxicity. Finally, to assess the effect of glutamine depletion on cell survival, we
quantified the percentage of live cells by flow cytometry and do not observe any
significant differences in viability in complete RPMI vs. glutamine-depleted RPMI for
either cell type under rest or stimulation (Figure 3.14). Similar to glucose depletion, this
indicates that these nutrients are specifically more important for T cell cytokine
production and cytotoxicity and not for their overall survival.
We also examined the mRNA expression of glutamine genes via NanoString, as
part of the annotated glutamine metabolism pathway in the Human Metabolic Pathways
panel. We did not observe significant differences between stimulated iNKT cells and
TCONV in these genes despite the difference in requirement for glutamine levels in culture
media for cytokine production and cytotoxicity (Figure 3.15). This could perhaps be that
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the timing or metabolic dynamics of mRNA expression for this pathway was not captured
during our 48-hour harvest, or that these differences in glutamine metabolism are not at
the RNA level – further studies looking at functional glutaminolysis activity in these cells
or metabolic tracing would be needed to dissect these dynamics. Regardless, our data
collectively demonstrate that iNKT cells are able to maintain their effector functions in
both glutamine-deplete and glucose-deplete media conditions, which may have
important consequences for their ability to exert anti-tumor immunity within the nutrientdeplete TME.

Human iNKT cells have a “memory-like” metabolic phenotype.
Memory T cells that develop after initial antigenic activation are primed for rapid
reactivation upon secondary antigenic encounter. To allow for greater self-renewal
capacity and longevity, memory T cells are metabolically adapted to possess altered
mitochondrial morphology with enhanced spare respiratory capacity and a predominant
reliance on oxidative and lipid metabolism (van der Windt et al., 2012, 2013b). We
postulated that human iNKT cells may be “memory-like” in their metabolism. iNKT cells
are poised for activation and express memory-like phenotypic markers, including CD62L,
CCR7, and CD45RO (Baev et al., 2004; D’Andrea et al., 2000). Furthermore, murine
NKT cells have been shown to depend on OXPHOS for survival, proliferation, and
effector functions relative to CD4+ T cells (Kumar et al., 2019). Collectively, it also
appears that iNKT cells do not have a distinct differentiation hierarchy of naïve, effector,
and memory states, further suggesting that their underlying metabolic program may be
unique from TCONV.
We first investigated mitochondrial parameters by flow cytometric dyes.
Specifically, we utilized MitoTracker Green, which provides a measure of mitochondrial
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mass, as well as tetramethylrhodamine methyl ester perchlorate (TMRM), a cell
permeable dye that accumulates in active mitochondria and serves as an indicator of
mitochondrial membrane potential. We found that both resting and stimulated human
iNKT cells have significantly higher mitochondrial mass (Figure 3.16A) and
mitochondrial membrane potential (Figure 3.16B) relative to unstimulated and
stimulated TCONV. Together, this may imply greater mitochondrial activity within iNKT
cells relative to TCONV. Furthermore, NanoString transcriptional profiling of these cells
revealed that resting and stimulated iNKT cells displayed significantly higher expression
of several fatty acid oxidation (FAO) enzyme transcripts than stimulated TCONV (Figure
3.16C and Table 3). These genes include Acaa2, a mitochondrial enzyme involved in
beta-oxidation of fatty acids into acetyl CoA, Acat1 and Acat2, which convert ketones
into acetyl-CoA, and Acox1, which also catalyzes beta-oxidation of fatty acids. One of
the most striking differences was in the expression of Cpt1a, which encodes the ratelimiting enzyme of FAO that transports long-chain fatty acids into the mitochondria to be
metabolized. Notably, Cpt1a was among the top 25 genes significantly higher in
stimulated iNKT cells than stimulated TCONV, underscoring the potential importance of
this enzyme for human iNKT cells. Indeed, in support of this transcriptional data, we also
find that stimulated iNKT cells possess significantly higher levels of intracellular Cpt1a
protein than rested iNKT cells and stimulated TCONV, as assessed by intracellular flow
cytometry (Figure 3.16D). These data suggest that iNKT cells may predominantly utilize
FAO metabolism upon stimulation, which could represent a key metabolic difference
from TCONV.
In TCONV, Cpt1a-mediated long-chain FAO supports the survival of memory T
cells and regulatory T cells (Michalek et al., 2011b; Pearce et al., 2009). One master
regulator that promotes FAO metabolism and memory cell differentiation is the nutrient
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sensor adenosine monophosphate-activated protein kinase (AMPK), which inhibits
mTORC1 to promote catabolism and FAO, particularly in conditions of nutrient stress
(Pearce et al., 2009; Rolf et al., 2013). To further investigate whether iNKT cells
displayed memory-like metabolism by employing FAO, we interrogated the expression of
the 29 annotated genes in the NanoString AMPK signaling pathway probe set in human
donor cell subsets. Intriguingly, of the 14 genes significantly differentially expressed
between stimulated iNKT cells and TCONV, 13 out of 14 were significantly higher in iNKT
cells than stimulated TCONV (Figure 3.16E). This further supports an important and
distinct role for FAO metabolism in human iNKT cells relative to TCONV.

Stimulated human iNKT cells oxidize fatty acids to a greater extent than stimulated
TCONV.
Given the striking differences in the expression of Cpt1a and other FAO genes
between stimulated human iNKT cells and TCONV, we postulated that these cells may
differ in their use of FAO metabolism. To investigate the dependence on FAO for the
metabolic activity of iNKT cells and TCONV upon stimulation, we performed Seahorse
extracellular flux analysis to generate real-time metabolic measurements of these cells.
To specifically determine the contribution of fatty acids to the oxygen consumption rate
(OCR) of stimulated iNKT cells and TCONV, we injected into the cells either media only
(vehicle) or etomoxir, a pharmacological inhibitor of Cpt1a. Upon etomoxir treatment,
long-chain fatty acid import into the mitochondria is blocked, such that cytosolic fatty
acids cannot be oxidized via the TCA cycle to fuel OXPHOS. Interestingly, we found that
upon addition of carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) – which
decouples the mitochondrial membrane to drive maximal substrate demand – etomoxirtreated iNKT cells displayed significantly reduced maximal respiration (Figure 3.17A,C).
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This indicates that fatty acids represent an important substrate for oxidation in stimulated
iNKT cells. In contrast, stimulated TCONV maintained equal levels of OCR upon FAO
inhibition (Figure 3.17B,C), implying that in these cells, fatty acids do not represent a
substrate for oxidation. In addition, we also quantified mitochondrial respiration-linked
ATP production, defined as the difference in OCR at baseline and upon injection of
oligomycin A, an ATP synthase inhibitor. Notably, this parameter was also significantly
lowered in etomoxir-treated iNKT cells, but not in TCONV (Figure 3.17D) further
supporting the importance of FAO for contributing to ATP production derived from
mitochondrial respiration in stimulated iNKT cells. Interestingly, depletion of fatty acids
did not completely ablate OCR activity of iNKT cells, as they still displayed heightened
respiration upon addition of FCCP above basal OCR levels. This may suggest that iNKT
cells do not solely depend on fatty acids and employ additional metabolic substrates for
energy consumption upon stimulation. Nevertheless, our findings ultimately reveal a key
bioenergetic difference between stimulated human iNKT cells and TCONV, whereby in
stimulated iNKT cells, fatty acids serve as a substrate contributing to fueling the TCA
cycle and OXPHOS, while TCONV preferentially rely on other substrates for oxidative
metabolism, such as glucose and glutamine.

Human iNKT cells do not depend on FAO metabolism for effector functions and may
utilize alternate pathways or exert metabolic flexibility
The differences observed in the oxidation of fatty acids between iNKT cells and
TCONV suggest that TCR-stimulated iNKT cells may be more reliant on FAO for their antitumor cytokine production and cytotoxicity, particularly since glucose and glutamine
were indispensable for these functions. To test the requirement of FAO metabolism for
effector functions, we treated rested and stimulated human iNKT cells and TCONV with
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etomoxir. Surprisingly, like TCONV, iNKT cells maintained equal levels of Ifng mRNA and
protein secretion upon stimulation with etomoxir treatment. We also utilized a higher
dose of etomoxir and observed similar results (Figure 3.18A-B). Furthermore, inhibition
of Cpt1a did not alter the cytotoxicity of iNKT cells, as stimulated iNKT cells maintained
similar levels of intracellular granzyme B (Figure 3.18C).
As an additional approach, we also tested whether depleted extracellular lipids
would affect iNKT cell effector functions – to do so, we rested and stimulated cells in
either normal AIM V media or media with charcoal-absorbed serum, from which lipids
are removed. While the response was variable across donors, in lipid-depleted media,
iNKT cells still retained levels of IFN-g and granzyme B and were not sensitive to the
absence of extracellular lipids (Figure 3.19).
Additionally, we also treated iNKT cells and TCONV with oligomycin A, an ATP
synthase inhibitor, to test the dependency on OXPHOS for effector functions. Once
again, TCONV were more sensitive to OXPHOS depletion for their IFN-g and granzyme B
production, while iNKT cells were still able to retain cytokine production and cytotoxicity
(Figure 3.20). Taken together, these data suggest that iNKT cells could be metabolically
flexible, in that they are able to maintain effector functions despite depletion of various
metabolic substrates (including glucose, glutamine and fatty acids) and pathways; if this
were the case, it could potentially endow iNKT cells a unique adaptability to biological
environments with different nutrient conditions. Alternatively, iNKT cells may utilize other
mechanisms or metabolic pathways to maintain their ability to produce cytokines and
exert cytotoxicity. These possibilities and the further exploratory studies needed to
delineate these mechanisms are discussed in the Discussion section below. Overall, our
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data suggest that human iNKT cells possess a unique metabolic profile from TCONV with
differential bioenergetic requirements for anti-tumor effector functions.

3.3. Discussion
Our data reveals for the first time that human iNKT cells possess a unique metabolic
profile from TCONV, characterized by greater FAO metabolism and a reduced requirement
for glucose and glutamine for anti-tumor effector functions upon activation (Figure 3.21).
Additionally, our data suggest that iNKT cells could possess metabolic flexibility,
whereby they may potentially have the capacity to utilize alternate metabolic pathways
as needed when a singular pathway is inhibited, in order to maintain effector functions.
Importantly, these differential bioenergetic requirements could have implications for the
ability of iNKT cells to retain functional activity within the nutrient-poor solid TME; if iNKT
cells are also more memory-like within the TME, they may possess an advantage in
competing with tumor cells relative to TCONV that could potentially be exploited
therapeutically. This would also allow for a broad range of functional capacity and
adaptability to many different nutrient-poor environments. Although our data
demonstrate many novel metabolic differences between human iNKT cells relative to
TCONV, there is still much to be further investigated in future studies to advance our
understanding of iNKT cell immunometabolism.
One observation we found when subjecting rested and stimulated iNKT cells and
TCONV to standard Seahorse metabolic flux analysis via Mito Stress tests and ATP Rate
Assay kits was that stimulated iNKT cells overall appeared to be less metabolically
active relative to both resting iNKT cells and stimulated TCONV, consistently displaying
lower oxygen consumption rates (OCR), extracellular acidification rates (ECAR) and
ATP production (Figure 3.22A-C). Additionally, upon 48-hour bead stimulation, iNKT cell
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viability is consistently significantly lower than TCONV. Although we plate equal numbers
of live cells (estimated by Trypan Blue counts) in the Seahorse assays, which should
normalize for this difference in viability, we postulated that perhaps by 48 hours, iNKT
cells could be apoptotic and not in their peak of full metabolic activity and functionality –
this could in turn account for the lowered metabolic activity we observe. As such, we
sought to test a shorter time point of activation to see whether we still found the same
trends of lower OCR and ECAR in stimulated iNKT cells relative to stimulated TCONV and
rested iNKT cells. To do so, we utilized the Human T cell Activation Seahorse test,
whereby cells are directly injected with soluble CD3 and CD28 in the Seahorse assay
and then subjected to continuous real-time measurements of OCR and ECAR at regular
intervals for up to 99 cycles (~10 hours). For these assays, we staggered the PBMC
expansion and sorting of iNKT cells such that one set would be sorted and rested for two
days and the other set would be sorted two days later and immediately plated in the
Seahorse assay post-sort. This resulted in testing the following conditions:
•

Post-sort, expanded iNKT cells injected with vehicle (media) only

•

Post-sort, expanded iNKT cells injected with soluble CD3+CD28 (“continued”
stimulation akin to 48-hour stimulations previously)

•

48-hour rested iNKT cells, injected with vehicle (“rest” condition similar to prior
assays)

•

48-hour rested iNKT cells, injected with soluble CD3+28 (extra condition of rest
and then secondary stimulation)

•

Unstimulated TCONV injected with vehicle only

•

Unstimulated TCONV injected with soluble CD3+28

•

48-hour Dynabead-stimulated TCONV (positive control)
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When subjecting these cells to this short-term activation assay, as expected, we
observed that unstimulated TCONV had a moderate increase in OCR and ECAR upon
injection with soluble CD3+28 relative to vehicle (to similar levels documented by Agilent
in prior assays), and that 48-hour bead-stimulated TCONV had very high OCR and ECAR.
Interestingly, iNKT cells displayed a very different pattern. Once again, both resting iNKT
cell populations had higher OCR and ECAR than even the post-sort, expanded iNKT
cells. Thus, despite these cells having been freshly expanded in culture and sorted (such
that the viability was >90%), they still were less metabolically active than rested cells
(Figure 3.22D). Therefore, even after normalizing for the type of stimulation (expansion
with α-GalCer + IL-2 + IL-15 vs. soluble CD3+28 vs. Dynabeads) and the time point
(acute activation vs. 48-hours), iNKT cells consistently displayed lower metabolic activity
upon stimulation. This is a particularly puzzling notion given that upon stimulation, iNKT
cells do induce high production of anti-tumor cytokines and cytotoxicity. Two possible
explanations for this could be (1) a difference in proliferation between iNKT cells and
TCONV upon stimulation, or (2) use of alternative metabolic pathways such as autophagy,
that could enable retained effector functions without the need for upregulated glycolysis
or OXPHOS metabolism.
We selected Ifng cytokine mRNA and secretion and intracellular granzyme B
levels as the main effector function readouts for our nutrient-depletion studies. However,
one key effector function to explore further would be proliferation. In TCONV, stimulationinduced metabolic reprogramming to increase glycolysis and glutamine metabolism –
while less ATP-generating –primarily allows for the generation of biosynthetic materials
to rapidly divide. Through this Warburg metabolism, TCONV activate biosynthesis of
nucleic acids and amino acids in addition to simply generating energy, as discussed in
Chapter 2. In our hands, based on the cell counts and morphology we observed, we
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believe that while bead-stimulated TCONV appear to proliferate in the duration of the 48
hours of stimulation, the iNKT cells likely do not to the same extent. Furthermore,
another striking difference we observed between stimulated iNKT cells and TCONV in
support of this notion was in their expression levels of Myc signaling genes. Stimulated
iNKT cells did not upregulate Myc signaling genes to the extent of TCONV, potentially
implying that they may not rely on Myc for effector functions. In TCONV, Myc is largely
upregulated not only to support enhanced glycolysis, but also proliferation (Wang et al.,
2011). Thus, it is quite likely that iNKT cells are either not proliferating upon stimulation
while producing cytokines and granzyme B, or potentially that only a small population of
the iNKT cells are proliferating while the majority die by 48 hours. Perhaps upon
stimulation, iNKT cells differentially divide their energy consumption to primarily support
cytokine production and cytotoxicity, while resting iNKT cells and stimulated TCONV need
more energy to support proliferative needs and thus exert higher metabolic activity.
Ultimately, these outcomes warrant further investigation by using assays like Cell Trace
Violet dye staining, which would allow the measurement of proliferation in these cells at
baseline, upon stimulation, and in normal media vs. nutrient-deplete conditions. A better
understanding of the proliferation dynamics of iNKT cells and how metabolism may be
differentially correlated to different effector functions could have very important
implications for the design of solid tumor cellular immunotherapies. Should iNKT cells
only be short-term effectors, this would affect how they are utilized for cellular
immunotherapies within the TME; alternatively, if certain subsets of iNKT cells possess
enhanced longevity and proliferative capacity, it would be important to determine how
these features correlate with underlying metabolism. Indeed, the implications for how our
immunometabolic discoveries could influence the design of cell-based immunotherapy
platforms for solid tumors are discussed at greater length in Chapter 4.
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An important remaining question in understanding iNKT cell immunometabolism
is whether these cells are metabolically “flexible”; i.e., do they utilize glycolysis,
glutaminolysis, or fatty acids for energy production and effector functions, but possess
the ability to switch between pathways accordingly when these nutrients are in short
supply? Or alternatively, do iNKT cells instead primarily rely on other metabolic
pathways or cellular mechanisms to preserve anti-tumor immunity? A key set of studies
to address whether iNKT cells are metabolically flexible would be to perform
combinations of nutrient-depletions in vitro. One limitation of our studies is that we only
depleted glucose, glutamine, and lipids individually. However, it would be valuable to
extend these studies by next treating cells with both double-depletion combinations of
these substrates, as well as depletion of all three nutrients, to observe whether iNKT
cells are still able to retain effector functions in these different conditions. This would
provide a more comprehensive understanding of which substrates and metabolic
pathways are required for effector functions. Furthermore, one could also more
thoroughly characterize the metabolic profile of iNKT cells in these different nutrient
depletion conditions by using gene expression analysis, Seahorse flux assays, and even
metabolomics analysis, to observe which, if any, compensatory pathways are utilized
when specific metabolic pathways are inhibited.
Additionally, it would also be beneficial to further delineate the contribution and
dynamics of lipid metabolism in iNKT cells. As discussed in Chapter 2, memory T cells
engage in de novo fatty acid synthesis through imported and stored triglycerides, which
allow them to more readily engage in cell-intrinsic FAO particularly in nutrient-deprivation
states (rather than relying on import of lipids from their extracellular environment)
(O’Sullivan et al., 2014). Furthermore, intratumoral iNKT cells were demonstrated to
uniquely upregulate lipid biosynthesis via PPAR-g and SREBP1 in a unique mechanism
70

that enables IFN-g production (Fu et al., 2020a). Thus, it is possible that iNKT cells do
not rely on extracellular lipids but rather are able to generate their own intracellularly.
Indeed, in the Seahorse assays we utilized, the etomoxir addition is effectively blocking
the import of fatty acids already present within the cell from entering the mitochondria to
be oxidized, as the Seahorse media does not contain fatty acids. Therefore, our results
that iNKT cells display reduced mitochondrial ATP production and maximal respiratory
capacity when this FAO is inhibited implies that they could perhaps have the ability to
breakdown intracellular lipids that they synthesize. This question could be probed by the
use of BODIPY flow cytometry dye staining, which detects intracellular lipids, as well as
CD36, a lipid transporter on the cell surface, to observe whether these are higher in
iNKT cells relative to TCONV. Additionally, it would also be beneficial to eventually conduct
lipidomics profiling to more thoroughly identify the types and quantification of lipids
present within these resting and stimulated cells. This could potentially enable a more
mechanistic understanding of the contribution of these lipids to effector functions in iNKT
cells relative to TCONV.
In addition to better understanding lipid metabolism, another potential future
experiment would be to investigate mitochondrial morphology in rested and stimulated
iNKT cells relative to TCONV. Given that we observe higher levels of mitochondrial mass
and membrane potential upon stimulation of iNKT cells, it is possible that they possess
further unique mitochondrial properties to enable FAO metabolism or resistance to
stress conditions. As discussed in Chapter 2, memory T cells not only undergo PGC1αinduced mitochondrial biogenesis to enable enhanced recall and survival, but also alter
their mitochondrial morphology such that their mitochondria undergo fusion to enable
more efficient ETC activity and ATP production. It would be very interesting to compare
the mitochondrial morphology of rested and stimulated iNKT cells by electron
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microscopy imaging to evaluate whether iNKT cells have more “memory-like”
mitochondria with tightly-folded, remodeled cristae. If iNKT cells displayed unique
mitochondrial morphology from effector TCONV, it could potentially enable these cells
more efficient mitochondrial metabolism and better adaptation to nutrient-stress
conditions.
Another potential explanation for both the low metabolic activity of stimulated
iNKT cells and their ability to retain effector functions upon depletion of glucose,
glutamine, or lipids in vitro, could be that iNKT cells utilize alternate metabolic pathways
than glycolysis and OXPHOS metabolism. Indeed, our NanoString transcriptional
profiling revealed differential expression of additional pathways between stimulated iNKT
cells and TCONV. In particular, both resting and stimulated iNKT cells displayed higher
expression levels of transcripts within the lysosomal degradation, endocytosis, and
autophagy pathways relative to stimulated TCONV (Figure 3.23 and Table 4). In line with
this data, AMPK pathway gene expression patterns were also higher in iNKT cells, and
AMPK can promote autophagy (Kim et al., 2011). Autophagy is an evolutionally
conserved, tightly controlled catabolic process by which cells turnover their intracellular
components (comprised of organelles, protein aggregates, and in some cases,
intracellular pathogens) through lysosomal degradation (Klionsky, 2007; Mizushima and
Komatsu, 2011). This process can serve as a basic mechanism of quality control and
homeostasis for cells, but also importantly provides an alternative source of energy in
nutrient-deplete conditions. Autophagy also preserves mitochondrial quality by removing
damaged mitochondria and preventing excess intracellular ROS (Pua et al., 2009).
Autophagy is maintained at a basal level in naïve T cells (Willinger and Flavell, 2012),
and there is some evidence that it can be induced in immune cells to facilitate functional
responses (Valdor and Macian, 2012). In particular, innate immune cells such as NK
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cells, dendritic cells, and macrophages utilize autophagy as part of their response to
pathogens, and indeed, autophagy-related genes can be directly upregulated by toll-like
receptors (TLRs) and nucleotide oligomerization domain (NOD)-like receptors expressed
on these cells (Delgado and Deretic, 2009; Carneiro and Travassos, 2013). Additionally,
inflammatory cytokines including IFN-g can also activate autophagy (Jiang et al., 2019;
Matsuzawa et al., 2012).
Although the role of autophagy in iNKT cells is not fully understood, there have
been studies demonstrating the role of this metabolic pathway in iNKT cell thymic
development. Specifically, genetic deletions of key autophagy genes result in reduced
frequencies, maturation, and proliferation of iNKT cells in the thymus, and interestingly,
reduced IFN-g cytokine production (Salio et al., 2014b; Pei et al., 2015). This provides
evidence for a potentially important cell-intrinsic role of autophagy for iNKT cell functions
that could also be important for their anti-tumor effector functions. It is possible that iNKT
cells could use this pathway as a fuel source upon stimulation in an innate-like manner
that is distinct from TCONV. Importantly, the ability to initiate lysosomal degradation and
autophagy could be an intriguing mechanism by which iNKT cells are able to adapt to
and retain effector functions within nutrient-deprived conditions. Thus, further studies
investigating the role of autophagy in iNKT cells – particularly in fueling anti-tumor
functions and facilitating survival and mitochondrial metabolism – are certainly
warranted. These findings could also have important implications for understanding how
iNKT cells may adapt and exert function within the nutrient-poor TME.
A final important future direction in advancing our understanding of iNKT cell
metabolism will be to profile specific subsets of iNKT cells to provide a more
comprehensive link between metabolic activity and effector functions. Because the
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present study was an initial characterization of primary human PBMC-derived iNKT cell
metabolism, we sorted and profiled rested and stimulated iNKT cells in bulk (i.e. all
expanded Vα24+CD3+ cells). However, like with TCONV, this may be a heterogenous
population containing different types of iNKT cells that each have unique phenotypic
marker expression, cytokine profiles, and metabolic and functional properties. In
addition, it would ultimately most beneficial to probe intratumoral iNKT cell metabolism
and effector functions, as these properties may vary within the context of the TME
relative to nutrient-depleted conditions in vitro. A further consideration of how to conduct
these future studies and their benefit to both the fields of immunometabolism and the
design of cellular immunotherapies is discussed in Chapter 4.

3.4. Methods
Human Primary Immune Cell Purification
Healthy, de-identified human donor peripheral mononuclear blood cells (PBMC) and
conventional T cells (TCONV) were purchased from the University of Pennsylvania Human
Immunology Core under an institutional review board-approved protocol. To obtain
sufficient yields of invariant natural killer (iNKT) cells, PBMC were plated in AIM V media
(Gibco) containing 500ng/mL alpha-galactosylceramide (Cayman Chemicals; KRN7000)
and 50U/mL recombinant IL-2 (PeproTech); on day 3-4 of culture, cells were fed with
10ng/mL recombinant IL-15 (BioLegend) and 10U/mL IL-2. On days 7-8 of expansion,
iNKT cells were FACS-sorted from expanded PBMC (Vα24+ CD3+ cells) on BD Aria II or
Aria Fusion instruments housed at the University of Pennsylvania and the Children’s
Hospital of Philadelphia Flow Cytometry Core Facilities, respectively. In parallel, purified
CD4+ and CD8+ T cells from matched donors were mixed at a 1:1 ratio to ensure equal
composition of TCONV populations.
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Cell Culture and Stimulation of Purified Lymphocytes
Purified iNKT and pooled TCONV (1:1 CD4+:CD8+) populations were subject to either “rest”
(low dose 30U/mL IL-2 only) or stimulation using Dynabeads Human T-Expander
CD3/28 (ThermoFisher Scientific) at 1 million cells/mL at a ratio of 2 beads per cell for
48 hours. For all studies of rested and stimulated cells under normal conditions
(transcriptional profiling and flow-based dyes), cells were cultured in AIM V media
containing 10% FBS and 1% L-glutamine. For glucose deprivation studies, cells were
rested and stimulated in complete RPMI 1640 media (Gibco) containing 10% dialyzed
FBS and 1% L-glutamine supplemented with either 10mM glucose, 1mM glucose, or
0.1mM glucose (Corning). For glutamine deprivation studies, cells were plated in either
complete RPMI media (containing 10% FBS and 1% L-glutamine at an approximate
concentration of 4mM glutamine total), or glutamine-free RPMI (Gibco) containing 10%
dialyzed FBS supplemented with 10mM glucose.

Flow Cytometry
To sort iNKT cells, the following antibodies were used for staining: anti-Vα24-Jα18
(clone 6B11; BioLegend #342912), anti-CD3 (clone OKT3; BioLegend #317318). For
staining of purified lymphocyte populations, cells were first stained with Zombie Aqua
fixable live/dead exclusion dye per manufacturer’s instructions (BioLegend cat #423101),
followed by surface staining in FACS buffer containing 2.5% FBS. For intracellular
staining, cells were fixed and permeabilized using the Becton Dickinson
Cytofix/Cytoperm kit, according to manufacturer’s instructions (BD Biosciences cat
#554714) and stained with antibodies against granzyme B (clone QA16A02; BioLegend
#372208) or mouse IgG1k isotype control (clone MOPC-21; BD Biosciences cat
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#556650), or Cpt1a (clone8F6AE9; Abcam cat# 171449) and rabbit IgG monoclonal
isotype control (clone EPR25A; Abcam cat# 199091). Samples were run on a
FACSVerse cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star
Inc.).

Mitochondrial Dye Staining
Purified rested and stimulated human iNKT cells and TCONV were harvested at 48 hours
for staining in either 200nM MitoTracker Green (Invitrogen cat #M7514) or 20nM
tetramethylrhodamine, methyl ester (TMRM; Invitrogen cat #T668) in serum-free RPMI
media for 45 minutes at 37°C per manufacturer’s protocol.

RNA Purification and Quantitative Real-Time PCR
Total RNA was isolated from rested and stimulated iNKT cells and TCONV using
miRNeasy Mini kit per manufacturer’s protocol (Qiagen). RNA was either hybridized for
NanoString transcriptional analysis or converted to cDNA for qPCR analysis. For gene
expression analysis of Ifng, cDNA was synthesized from purified mRNA using High
Capacity Reverse Transcriptase kit (Applied Biosystems) according to manufacturer’s
protocol. Quantitative real-time PCR was performed on 7900HT Fast Real-Time PCR
system (Applied Biosystems). Relative gene expression was calculated by normalizing
delta Ct values for each target probe to Actb levels for each sample using the 2-ΔCt
method. The following TaqMan Gene Expression Assays (Life Technologies) were used:
human Ifng (Hs_00989291_m1), human Actb (Hs01060665_g1).

NanoString nCounter Gene Expression Profiling and Analysis
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All transcriptional profiling of mRNA isolated from rested and stimulated human iNKT
cells and TCONV was performed using the nCounter SPRINT Profiler (NanoString
Technologies). For early analysis of metabolic pathways of subsets of iNKT cells and
TCONV, we utilized the nCounter 3D RNA Vantage Cancer Metabolism Panel, containing
a code set with probes for 180 metabolism-related human genes and 12 internal
reference controls, plus an extension TagSet of 38 additional genes pertaining to
immune cell activation, lipid metabolism, and hypoxia genes. For more extensive
transcriptional profiling of bulk rested and stimulated iNKT cells and unstimulated and
stimulated pooled CD4+:CD8+ TCONV, we utilized reporter and capture probe sets for the
Human Metabolic Pathways panel, containing 768 genes across several annotated
metabolic pathways and 20 internal reference genes.
For both tests, per manufacturer’s instructions, 50ng of each RNA sample was
hybridized for either 24 hours at 67ºC (Vantage) or 18 hours at 65ºC (Metabolic
Pathways). After this step, hybridized RNA samples were loaded onto nCounter SPRINT
cartridge to run on SPRINT Profiler instrument. Gene expression analysis was
conducted using NanoString nSolver 4.0 software. Genes with counts under 100 were
eliminated from analysis. Heatmaps were generated using Morpheus
(https://software.broadinstitute.org/morpheus).

Cytokine Analysis
Supernatants from 48-hour rested and stimulated iNKT cells and TCONV were assayed for
cytokine levels of IFN-g using human ELISA kit (Invitrogen cat #88-7316) following
manufacturer’s protocol. Quantification of TNF-α and IL-4 cytokines in supernatants was
performed using V-Plex Pro-Inflammatory Panel 1 Human Kit (Meso Scale Discovery,
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cat #K15049D). Assays were performed per manufacturer’s protocol and read and
analyzed on a Meso Scale Discovery QuickPlex SQ120 instrument.

Metabolic inhibitors
For inhibition of glucose metabolism, 2-deoxy-D-glucose (Sigma cat # D6134) was
added to rested and stimulated iNKT cells and TCONV at concentrations of either 2mM or
20mM for 48 hours. For inhibition of fatty acid oxidation (Cpt1a), etomoxir (Sigma cat #
E1905) was added to cells at concentrations of either 5µM or 100µM for 48 hours. For
inhibition of OXPHOS (ATP synthase), oligomycin A (Sigma cat# 75351) was added to
cells at a concentration of 1µM for 48 hours.

Seahorse XF Metabolic Analysis
Real-time metabolic measurements of oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) of iNKT cells and TCONV from matched donors were obtained
using XFe96 Extracellular Flux Analyzer (Seahorse Biosciences). For all tests, on the
day prior to assay, XF cartridge was hydrated, and XF tissue microplates were coated
with Cell Tak (Corning cat #354240) per manufacturer’s protocol. On the day of the
assay, rested and stimulated iNKT cells and TCONV were washed and seeded at a density
of 220,000 cells per well on pre-coated tissue microplates in XF RPMI assay media (pH
7.4) supplemented with 10mM glucose, 2mM L-glutamine, and 1mM pyruvate. Cells
were spun down at 1500rpm for 3 minutes to facilitate adherence and placed in non-CO2
incubator for one hour prior to running assay.
The XF Long-Chain Fatty Acid Substrate Oxidation kit (Agilent cat #103672-100) was
utilized to probe differences in OCR upon injection with either vehicle (media only) or
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etomoxir (4µM) to inhibit long-chain fatty acid oxidation. Following three basal
measurements of OCR and ECAR, cells were sequentially injected with 1.5µM
oligomycin A (ATP synthase inhibitor; Agilent Technologies), 0.5µM FCCP
(mitochondrial uncoupling agent; Agilent Technologies), and 0.5µM rotenone/antimycin
A (mitochondrial complex I and III inhibitors; Agilent Technologies). After injection of
oligomycin A, six readings were taken; after the following two sequential injections, three
readings were taken. Maximal respiration was calculated as the difference between
OCR upon FCCP injection and non-mitochondrial respiration (OCR upon rotenone and
antimycin A injection). ATP production was calculated as the difference in OCR prior to
and after oligomycin A injection.
The XF Cell Mito Stress test kit (Agilent cat # 103015-100) was utilized to measure OCR
and ECAR as well as mitochondrial functional parameters in rested and stimulated iNKT
cells and TCONV. Following three basal measurements of OCR and ECAR, cells were
sequentially injected with 1.5µM oligomycin A (ATP synthase inhibitor; Agilent
Technologies), 0.5µM or 1µM FCCP (mitochondrial uncoupling agent; Agilent
Technologies), and 0.5µM rotenone/antimycin A (mitochondrial complex I and III
inhibitors; Agilent Technologies), similar to the LC-FAO test above. Three basal OCR
and ECAR readings were taken, and three readings each were taken after each
sequential injection of inhibitor.
For testing acute activation of freshly expanded iNKT cells relative to rested cells, the XF
Hu T Cell Activation methodology was used – for this assay, three basal OCAR and
ECAR measurements were recorded, followed by injection of either XF RPMI media only
(the first time containing 10mM glucose, 2mM L-glutamine, and 1mM pyruvate and
second time without these supplements added), or Immunocult Human CD3/28 Activator
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(STEMCELL Technologies cat # 10971) diluted at a 1:1 ratio in Seahorse media, per
manufacturer’s instructions. Following this injection, OCR and ECAR readings were
mixed and measured repeatedly for up to 99 cycles (approximately 10 hours).

Statistical Analyses
For comparison of relative fold-changes in mRNA, ELISA, and Seahorse assays,
unpaired student’s t-tests were utilized to assess significance between groups. For flow
cytometry data assessing mean fluorescent intensity values in iNKT cells and TCONV (e.g.
granzyme B, Cpt1a, MitoTracker, and TMRM), two-way analysis of variance (ANOVA)
analyses were performed. To assess dose-dependence of glucose concentration on
mean fluorescent values of stimulated iNKT cells and TCONV, simple linear regression
was conducted. As denoted in the figure legends, significance was indicated by p<0.05
(*), p<0.01 (**), and p<0.001 (***). All graphs and statistical analyses were conducted
using GraphPad Prism software.
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3.5. Tables

Table 3.1: Glycolysis pathway gene set expression in stimulated iNKT cells and TCONV
p-value

q-value

Higher expressing
cell subset

PFKL

1.8003E-05

1.6498E-04

iNKT

PFKM

2.7224E-05

1.6498E-04

TCONV

HK2

7.0098E-05

2.8319E-04

TCONV

LDHA

1.2875E-04

3.9011E-04

TCONV

LDHB

2.0950E-04

4.2319E-04

TCONV

ALDOA

6.6621E-03

1.0093E-02

TCONV

ENO1

1.8666E-02

2.1844E-02

TCONV

GAPDH

1.9826E-02

2.1844E-02

TCONV

PDHA1

2.7659E-02

2.7936E-02

TCONV

PGM2

7.5981E-02

6.5778E-02

TCONV

HK1

1.2941E-01

1.0457E-01

iNKT

PKM

2.0838E-01

1.5785E-01

iNKT

PGK1

9.5339E-01

6.0816E-01

iNKT

Gene name
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Table 3.2: Myc pathway gene set expression in stimulated iNKT vs. TCONV
Gene name

p-value

q-value

Higher expressing
cell subset

ODC1

1.7854E-10

1.4426E-09

TCONV

MYC

1.9047E-08

7.6950E-08

TCONV

HSPE1

1.5100E-06

4.0670E-06

TCONV

NME1

3.0130E-06

6.0862E-06

TCONV

NME2

4.3946E-06

7.1017E-06

TCONV

CAD

1.5126E-05

2.0369E-05

TCONV

HERC1

6.1085E-05

7.0510E-05

iNKT

LDHA

1.2875E-04

1.3004E-04

TCONV

SRM

2.3461E-04

2.1063E-04

TCONV

RPL23

1.0744E-03

8.6815E-04

TCONV

FASN

1.5111E-02

1.1100E-02

TCONV

ENO1

1.8666E-02

1.2568E-02

TCONV

TFRC

5.8868E-02

3.6589E-02

TCONV

FASLG

7.2688E-02

4.1952E-02

iNKT

PPAT

1.3568E-01

7.3088E-02

TCONV

CCNA2

1.8492E-01

9.3383E-02

iNKT

HSPA4

4.1727E-01

1.9833E-01

TCONV

TP53

7.4413E-01

3.3403E-01

TCONV
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Table 3.3: Fatty acid oxidation (FAO) pathway gene set expression in stimulated iNKT vs.
TCONV

p-value

q-value

Higher
expressing cell
subset

CPT1A

1.8304E-08

9.2435E-08

iNKT

ACAA2

2.2474E-07

5.6746E-07

iNKT

ACAT2

1.7960E-05

3.0232E-05

iNKT

ACOX1

1.1788E-03

1.4883E-03

iNKT

ACAT1

8.2236E-03

8.3058E-03

iNKT

PRKAB2

1.9726E-01

1.6603E-01

iNKT

HADH

2.3673E-01

1.6985E-01

iNKT

PRKAG2

2.6907E-01

1.6985E-01

TCONV

ECHS1

9.4583E-01

5.3072E-01

iNKT

Gene name
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Table 3.4: Summary of key pathways differentially expressed in stimulated iNKT vs. TCONV.

Pathway

# in top 100

Higher
in iNKT

Higher
in
TCONV

Cytokine &
chemokine
signaling/cytotoxic
markers

26
(~20% of
total)

22/26

4/26

Cell cycle

12 (18% of
total)

10/12

2/12

Amino acid
synthesis

11 (12% of
total)

5/11

6/11

Gene names

•

iNKT: top 4: TBK1, GNLY,
GZMA, PRF1
Tconv: STAT6, CD27, MYC,
IL21R

•

iNKT top 5: BUB1, CCNB2,
CENPA, GTSE1, CDCA8
•
Tconv: NPM1, MYC

•

•
•

Autophagy

9 (18% of
total)

9/9

0/9

Mitochondrial
respiration

8 (13% of
total)

4/8

4/8

iNKT: IL4I1, FAH, ASL,
ACAA2, ACAT2
Tconv: OCD1, MAT2A, CAD,
ASNS, PHGDH, LDHB

CTSD, ERN1, MAPK8, GABARAP,
PIK3CD, PTEN, PRKAA1, CHMP6,
PIK3R1
•

iNKT: SLC16A3, NDUFB1,
COX8A, PDK2
Tconv: TFAM, SLC16A1,
PEMT, LDHA

•
Myc

8 (45% of
total)

0/8

8/8

Endocytosis

7 (19% of
total)

6/7

1/7

Lysosomal
degradation

5 (38% of
total)

5/5

0/5

TLR signaling

5 (13% of
total)

4/5

1/5

Glycolysis

4 (21% of
total)

0/4

4/4

Glutamine
metabolism

4 (13% of
total)

2/4

2/4

Antigen
presentation

4 (11% of
total)

4/4

0/4

LAG3, CTSD, VHL, HLA-DRB1

ROS

3 (12.5% of
total)

3/3

0/3

IDH1, NQO1, CAT

Fatty acid
oxidation

2 (22% of
total)

2/2

0/2

CPT1A, ACAA2
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ODC1, NPM1, CAD, NME2, NME1,
HSPE1, MYC, LDHA
•

iNKT: CD4, SLC2A8, CBL,
SMAD3, HSPA2, CHMP6
•
Tconv: EEA1

CTSD, CD63, CTSW, GBA, CTSZ
•

iNKT: TBK1, MAPK8, ITGAM,
ITGB2
•
Tconv: EEA1
PFKM, LDHB, LDHA HK2
•
•

iNKT: GLRX, SERINC5
Tconv: ASNS, PHGDH

3.6. Figures

Figure 3.1: Determining optimal rest and stimulation conditions for expanded iNKT cells.
Bulk PBMCs were expanded for 7 days in culture and iNKT cells (Vα24+CD3+) were collected by
FACS-sorting. (A) RNA was harvested from iNKT cells either immediately post-sort or after 24
hours, 48 hours, or 72 hours of ”resting” culture (30U/mL (low-dose) IL-2) and assessed for Ifng
mRNA expression via qPCR (values normalized to Actb expression). Matching TCONV were also
sorted from expanded PBMCs, rested in culture as indicated, and assessed for Ifng expression in
parallel. (B) FACS-sorted iNKT cells were assessed for Ifng mRNA expressed (normalized to
Actb expression) immediately post-8 days of expansion or under different stimulation conditions
in AIM V media for 48 hours: rest (low-dose IL-2 only), 1:1 Dynabeads, 3:1 Dynabeads, or
333ng/mL alpha-galactosylceramide and 10ng/mL IL-15 (“continued” expansion, i.e. final
concentrations at day 8 pre-sorting).
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Figure 3.2: Expanded iNKT cells have unique metabolic transcriptional profiles from that
of conventional T cells (TCONV) subsets.
Bulk PBMCs and bulk purified T cells from two healthy human donors were obtained from the
UPenn Human Immunology Core. T cells were cultured in media containing low-dose (30U/ml) IL2 alone (unstimulated) or with anti-CD3+CD28 Dynabeads at a 3:1 ratio for 2 days (2d stim),
followed by FACS-sorting for CD8+ and CD4+ subsets. iNKT cells were purified from matched
donor bulk PBMCs by expansion scheme in Methods section (3.4) and Figure 3.3. On day 7 of
expansion cells were FACS-sorted for iNKT cell subsets (CD4+, CD8+, or double-negative within
Va24+Vb11+CD56+ cells). RNA was prepared from all sorted samples and nCounter Vantage
Cancer Metabolism NanoString panel with Extension Tagset was performed on SPRINT machine
according to Nanostring protocol. Data was normalized on NanoString nSolver 3.0 software.
Genes with counts >100 eliminated from analysis. Heatmaps of normalized Log2 values were
generated using Morpheus.
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Figure 3.3: Expansion and stimulation scheme for purifying healthy human donor PBMCderived iNKT cells and conventional T cells (TCONV). Schematic depicting obtaining and
expanding purified human donor cells from UPenn Human Immunology Core. For all studies,
iNKT cells were expanded, FACS-sorted, and rested as indicated. CD4+ and CD8+ conventional T
cells (TCONV) from matched sets of human donors were mixed at a 1:1 ratio to ensure equal
composition of these subsets for consistency in all studies. Matched iNKT cells TCONV and were
subjected to 48 hours of “rest” and “stimulation” with CD3/CD28 Dynabeads as indicated. Images
created using BioRender.
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Figure 3.4: Human iNKT cells do not depend on glucose for effector functions relative to
TCONV. Sorted PBMC-derived iNKT cells and TCONV were rested or stimulated in RPMI media
containing 10mM, 1mM, or 0.1mM glucose for 48 hours per schematic in Supplemental Figure 1.
(A) mRNA expression of Ifng was determined for iNKT cells (left) and TCONV (right) at 48 hours by
qPCR (with values normalized to Actb expression). Fold change induction of Ifng upon stimulation
relative to rest (iNKT) and unstimulated (TCONV) conditions displayed. Each symbol represents
matched, independent human donor biological replicates. (B) Summary data depicting fold
change in Ifng Ct values upon stimulation from qPCR in (A), relative to 10mM glucose, for iNKT
and TCONV (C) Supernatants were collected from rested and stimulated iNKT cells (left) and TCONV
(right) after 48 hours. IFN-g levels were detected via ELISA and fold change upregulation upon
stimulation relative to rest (iNKT) and unstimulated (TCONV) conditions displayed. Each symbol
represents matched, independent human donor biological replicates. (D) Summary data depicting
fold change in IFN-g secretion upon stimulation from ELISA in (C), relative to 10mM glucose, for
iNKT and TCONV. (E) Rested and stimulated iNKT cells and TCONV from matched human donors
were stained for intracellular Granzyme B or isotype control; histogram of live, stimulated iNKT
cells and TCONV representative of 4 matched, independent human donor samples. (F)
Quantification of granzyme B mean fluorescence intensity (MFI) of stimulated iNKT cells and
TCONV normalized to isotype MFI indicated in bar graph. In all graphs, asterisks denote statistical
significance (*p<0.05, **p<0.01, ***p<0.001) determined by unpaired, two-way student’s t tests in
(B) and (D) and simple linear regression test in (F). For all studies, biological replicates of human
donor samples are indicated by symbols, and n=4 technical replicates were performed. Each
biological replicate of matched donor cells was run in independent experiments.
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Figure 3.5: Human iNKT cells maintain secretion of additional cytokines in glucosedepleted media relative to TCONV. Supernatants were collected from rested and stimulated iNKT
cells and TCONV cultured in 10mM, 1mM, or 0.1mM glucose after 48 hours. Secreted TNF-α (A)
and IL-4 (B) were quantified via MSD Multiplex Assay. Summary data of percent change in fold
change upon stimulation for 3 independent, matched human donors depicted in bar graphs for
stimulated iNKT cells (dark grey) and stimulated TCONV (light grey).
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Figure 3.6: Absolute levels of Ifng mRNA expression and protein secretion for rested iNKT
cells and unstimulated TCONV upon glucose depletions.
(A) Delta Ct values of Ifng mRNA (normalized to Actb expression) for rested iNKT cells and
unstimulated TCONV after 48 hours. (B) IFN-g concentration in supernatants collected at 48 hours
detected by ELISA for rested iNKT cells. Unstimulated TCONV not shown, as values were all zero.
For all figures, each individual symbol represents independent human donor sample.

90

Figure 3.7: Glucose depletion does not significantly affect viability of human iNKT cells or
TCONV. Bar graph depicts percentage of live (Zombie Aqua negative) cells out of total singlets in
each cell type. Each dot represents a different donor (n=2 matched donors; for iNKT cells, n=4
total and TCONV, n=3 total), and legend indicates the different cell subsets. None of the groups
displayed statistically significant differences in viability between 10mM, 1mM, and 0.1mM glucose
conditions after 48 hours of culture.
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Figure 3.8: Human iNKT cells are less sensitive to pharmacological inhibition of glycolysis
than TCONV. (A) Sorted PBMC-derived iNKT cells and TCONV were rested or stimulated for 48
hours in complete AIM V media with low-dose IL-2 (30U/mL) only or containing either 2mM or
20mM 2-Deoxy-D-glucose (2-DG). Supernatants from rested and stimulated iNKT cells and TCONV
cultured in each condition were collected after 48 hours and profiled for levels of IFN-g via ELISA.
Fold change in IFN-g secretion upon stimulation is displayed for iNKT cells (left) and TCONV (right)
relative to rest and unstimulated conditions, respectively. (B) Stimulated iNKT cells and TCONV
were stained for intracellular Granzyme B or isotype control after 48 hours of indicated
treatments. Bar graph depicts mean fluorescence intensity (MFI) of granzyme B relative to
isotype control. Each dot represents independent, matched human donor sample.
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Figure 3.9: Human iNKT cells are less glycolytic than TCONV. (A) (Left) Heatmap of 8
independent, healthy human donor rested and stimulated iNKT cells and matched TCONV
(processed per schematic in Figure 3.3) transcriptional profiles for genes in the glycolysis
pathway included in the NanoString nCounter Human Metabolic Pathways probe set. Genes with
counts under 100 were eliminated from analysis. Coloring indicates relative expression of each
gene, from low (blue) to high (red). Heatmap generated on Morpheus. (Right) Schematic of
glycolytic pathway enzymes. Red text indicates genes significantly higher in stimulated TCONV
relative to stimulated iNKT cells, black text are not significantly different, and purple text is
significantly higher in stimulated iNKT cells relative to stimulated TCONV. Image created using
BioRender. (B) Pie chart graphically displaying proportion of glycolysis genes significantly higher
in each stimulated cell subset.

93

Figure 3.10: Stimulated human iNKT cells have lower expression of Myc signaling genes
than TCONV. (A) Heatmap of n=8 independent, matched healthy human donor-derived rested and
stimulated iNKT and TCONV (processed per schematic in Figure 3.3) relative expression of Myc
pathway genes in NanoString nCounter Human Metabolic Pathways probe set. Genes with
counts under 100 were eliminated from analysis. Coloring indicates relative expression of each
gene, from low (blue) to high (red). Heatmap generated on Morpheus. (B) Pie charts displaying
statistical analysis of NanoString Myc pathway genes from (A). Proportions of genes significantly
different in stimulated iNKT vs. stimulated TCONV depicted (left), and of those genes, percentages
significantly higher in TCONV and iNKT shown (right).
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Figure 3.11: Human iNKT cells are less reliant on glutamine for effector functions than

TCONV. Sorted PBMC-derived iNKT cells and TCONV were rested or stimulated in either complete
RPMI (10% FBS, 1% L-glutamine) or glutamine-free RPMI media for 48 hours per schematic in
Supplemental Figure 1. (A) mRNA expression of Ifng was determined for iNKT cells (left) and
TCONV (right) at 48 hours by qPCR (with values normalized to Actb expression). Fold change
induction of Ifng upon stimulation relative to rest (iNKT) and unstimulated (TCONV) conditions
displayed. Each symbol represents matched, independent human donor biological replicates. (B)
Summary data of fold change in Ifng Ct upon stimulation relative to cRPMI condition is depicted
for iNKT and TCONV from qPCR in (A). (C) Supernatants were collected from rested and
stimulated iNKT cells (left) and TCONV (right) after 48 hours. IFN-g levels were detected via ELISA
and fold change upregulation upon stimulation relative to rest (iNKT) and unstimulated (TCONV)
conditions displayed. Each symbol represents matched, independent human donor replicates. (D)
Summary data of change in IFN-g secretion fold change upon stimulation relative to cRPMI is
depicted for iNKT and TCONV from ELISA in (C). (E) Rested and stimulated iNKT cells and TCONV
from matched human donors were stained for intracellular Granzyme B or isotype control;
histogram of live, stimulated iNKT cells and TCONV representative of 4 matched, independent
human donor samples. (F) Quantification of granzyme B mean fluorescence intensity (MFI) of
stimulated iNKT cells and TCONV normalized to isotype MFI indicated in bar graph. In all graphs,
asterisks denote statistical significance (*p<0.05, **p<0.01, ***p<0.001) determined by unpaired,
two-way student’s t tests in (B) and (D) and two-way analysis of variance (ANOVA) analysis in
(F). For all studies, biological replicates of human donor samples are indicated by symbols, and
n=4 technical replicates were performed. Each biological replicate of matched donor cells was
run in independent experiments.
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Figure 3.12: Glutamine is not required for secretion of additional cytokines in human iNKT
cells upon stimulation. Supernatants were collected from rested and stimulated iNKT cells and
TCONV cultured in either complete RPMI media or glutamine-depleted RPMI media conditions after
48 hours. Secreted TNF-α (A) and IL-4 (B) were quantified via MSD Multiplex Assay. Summary
data of percent change in fold change upon stimulation for 4 independent, matched human
donors depicted in bar graphs for stimulated iNKT cells (dark grey) and stimulated TCONV (light
grey).
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Figure 3.13: Absolute levels of Ifng mRNA and secreted protein for rested iNKT cells and
unstimulated TCONV upon glutamine depletion. (A) Delta Ct values of Ifng mRNA (normalized
to Actb expression) for rested iNKT cells and unstimulated TCONV after 48 hours. (B) IFN-g
concentration in supernatants collected at 48 hours detected by ELISA for rested iNKT cells.
Unstimulated TCONV not shown, as values were all zero. For all figures, each individual symbol
represents independent human donor sample.
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Figure 3.14: Glutamine depletion does not significantly alter viability of human resting or
stimulated iNKT cells or TCONV. Bar graph depicts the percentage of live (Zombie Aqua
negative) cells out of total singlets in each cell type. Each dot represents a different donor (n=4
matched sets), and key indicates the different cell subsets. None of the groups displayed
statistically significant differences in viability between cRPMI and glutamine-free RPMI after 48
hours of culture.
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Figure 3.15: Stimulated human iNKT cells and TCONV do not have significantly different
expression of glutamine metabolic genes. Heatmap of n=8 independent, matched healthy
human donor-derived rested and stimulated iNKT and TCONV (processed per schematic in Figure
3.3) relative expression of glutamine metabolism pathway genes in NanoString nCounter Human
Metabolic Pathways probe set. Genes with counts under 100 were eliminated from analysis.
Coloring indicates relative expression of each gene, from low (blue) to high (red). Heatmap
generated on Morpheus.
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Figure 3.16: Human iNKT cells possess enhanced mitochondrial metabolism and FAO
relative to TCONV. (A) Histograms (left) displaying mean fluorescence intensity (MFI) of
MitoTracker Green emission (FITC channel) in purified rested and stimulated iNKT cells and
TCONV from n=3 matching human donor biological replicates run in independent experiments
(Right) Bar graphs of MFIs. Symbols represent independent, matched human donors. (B)
Histograms (left) displaying mean fluorescence intensity (MFI) of TMRM emission (PE channel) in
purified rested and stimulated iNKT cells and TCONV from n=3 matching human donor biological
replicates run in independent experiments. (Right) Bar graphs of MFIs. Symbols represent
independent, matched human donors. (C) Heatmap of n=8 independent biological replicates of
matched healthy human donor rested and stimulated iNKT cells and TCONV (processed per
schematic in Supplemental Figure 1) relative expression of fatty acid oxidation (FAO) pathway
genes in NanoString nCounter Human Metabolic Pathways probe set. Genes with counts under
100 were eliminated from analysis. Coloring indicates relative expression of each gene, from low
(blue) to high (red). Heatmap generated on Morpheus. (D) Purified rested and stimulated human
iNKT cells and TCONV were stained for intracellular Cpt1a expression after 48 hours. Mean
fluorescence intensity (MFI) of Cpt1a (left) and percentage of Cpt1a positive cells (right) for each
cell type relative to isotype control indicated. Each symbol represents matched healthy human
donor sample; each biological replicate set of cells was run in independent experiments. (E)
Heatmap of n=8 independent biological replicates of matched healthy human donor rested and
stimulated iNKT and TCONV relative expression of AMPK pathway genes in NanoString nCounter
Human Metabolic Pathways probe set analyzed as in (C). For studies comparing mean
fluorescence intensity values (A, B, D), statistical significance between groups (* p<0.05, **
p<0.01, ***p<0.001) was determined by two-way ANOVA tests and indicated on the bottom of
each graph. For NanoString data in (C) and (E), each set of matched donor biological replicates
was independently collected, stimulated, and harvested for mRNA and all samples were run and
analyzed on NanoString together.
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Figure 3.17: Stimulated human iNKT cells oxidize fatty acids more than stimulated TCONV.
(A-B) Real-time measurements of oxygen consumption rate (OCR) of 48-hour stimulated iNKT
cells (A) and stimulated TCONV (B) from matched human donors were obtained on a Seahorse
Bioanalyzer. OCR was measured after sequential additions of media (vehicle, black) or 4µM
etomoxir (red) followed by 1.5µM oligomycin A, 0.5µM FCCP, and 0.5µM rotenone and antimycin
A. Graphs depict representative example of 3 independent, matched human donor replicates. (C)
Summary data displaying the percent change in maximal OCR upon FCCP (mitochondrial
uncoupler) injection with pre-injection of etomoxir relative to vehicle controls for stimulated iNKT
cells (dark grey) and stimulated TCONV (light grey). Graphs depict summary data from 3
independent matched human donors. Asterisks indicate statistical significance (* p<0.05, **
p<0.01). (D) Summary data displaying the percent change in ATP production with etomoxir
addition relative to vehicle controls for stimulated iNKT cells (dark grey) and stimulated TCONV
(light grey). Graphs depict summary data from 3 independent matched human donors. Asterisks
indicate statistical significance (* p<0.05, ** p<0.01).
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Figure 3.18: Human iNKT cells are not dependent on FAO for effector function. Sorted
PBMC-derived iNKT cells (left) and TCONV (right) were rested or stimulated in complete AIM V
media with low-dose IL-2 (30U/mL) only or containing 5µM or 100µM etomoxir (etx) for 48 hours
per schematic in Figure 3.3. (A) mRNA expression of Ifng after 48 hours was determined by
qPCR and normalized to Actb expression. Fold change induction of Ifng upon stimulation relative
to rest (iNKT) and unstimulated (TCONV) conditions displayed. (B) Supernatants were collected
from rested and stimulated iNKT cells (left) and TCONV (right) after 48 hours. IFN-g levels were
detected via ELISA and fold change upregulation upon stimulation relative to rest (iNKT) and
unstimulated (TCONV) conditions displayed. (C) Stimulated iNKT cells and TCONV were stained for
intracellular Granzyme B or isotype control after 48 hours of indicated treatments. Bar graph
depicts mean fluorescence intensity (MFI) of granzyme B relative to isotype control.
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Figure 3.19: Human iNKT cells are not sensitive to extracellular lipid depletion for effector
functions in vitro. (A) Sorted PBMC-derived iNKT cells (left) and TCONV (right) were rested or
stimulated in complete AIM V media containing normal FBS or charcoal-absorbed serum (lipiddepleted) for 48 hours. mRNA expression of Ifng after 48 hours was determined by qPCR and
normalized to Actb expression. Each dot represents independent human donor sample. (B)
Supernatants were collected and analyzed from rested and stimulated iNKT cells and TCONV after
48 hours in indicated conditions. IFN-g secretion was detected via ELISA analysis. Fold change in
IFNg secretion upon stimulation is displayed for iNKT cells (left) and TCONV (right). Each dot
represents independent human donor sample. (C) Stimulated iNKT cells and TCONV were stained
for intracellular Granzyme B or isotype control after 48 hours of indicated treatments. Bar graph
depicts mean fluorescence intensity (MFI) of granzyme B relative to isotype control.
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Figure 3.20: Human iNKT cells are less sensitive to pharmacological inhibition of OXPHOS
than TCONV. (A) Sorted PBMC-derived iNKT cells (left) and TCONV (right) were rested or stimulated
in complete AIM V media with low-dose IL-2 (30U/mL) only or containing 1µM oligomycin A for 48
hours. Supernatants from rested and stimulated iNKT cells and TCONV were collected after 48
hours and profiled for levels of IFN-g via ELISA. Fold change in IFN-g secretion upon stimulation
is displayed for iNKT cells (left) and TCONV (right). (B) Stimulated iNKT cells and TCONV were
stained for intracellular Granzyme B or isotype control after 48 hours of indicated treatments. Bar
graph depicts mean fluorescence intensity (MFI) of granzyme B relative to isotype control.
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Figure 3.21: Working model summarizing differences in bioenergetic requirements for
effector functions between human iNKT cells and TCONV.
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Figure 3.22: Stimulated human iNKT cells are less metabolically active than stimulated
TCONV or rested iNKT cells. Rested and stimulated iNKT cells and TCONV from matched human
donors were subjected to real-time metabolic flux analyses via Seahorse Bioanalyzer. (A) XF
ATP Rate Assay was utilized to measure oxygen consumption rate (OCR) (top) and extracellular
acidification rate (ECAR) (bottom) of cells upon sequential additions of 1µM oligomycin A and
0.5µM rotenone and antimycin A. (B) Bar graph depicting total ATP production, and the
proportions derived from mitochondrial ATP (blue) vs. glycolytic ATP (red) for each cell type. Data
representative of two independent donor replicates. (C) XF Mito Stress test was utilized to
measure OCR (top) and ECAR (bottom) of cells upon sequential additions of 1.5µM oligomycin A,
either 0.5µM or 1µM FCCP, and 0.5µM rotenone and antimycin A, as indicated in the graph
legend. Data representative of two independent donor replicates. (D) XF Hu T Cell Activation kit
was utilized to measure OCR and ECAR of cells upon injection with either vehicle only (XF media
only) or Immunocult Human CD3/28 T cell Activator. iNKT cells and TCONV were either prestimulated with CD3+28 Dynabeads, rested for 48 hours prior to Seahorse assay, or plated
directly post-sorting (see discussion section for more details on assay setup).
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Figure 3.23: Human iNKT cells have differential expression patterns of genes in
autophagy, lysosomal degradation, and endocytosis pathways from TCONV.
Heatmap of n=8 independent, matched healthy human donor rested and stimulated iNKT cells
and TCONV relative expression of autophagy (A), lysosomal degradation (B), and endocytosis (C)
gene pathways in NanoString nCounter Human Metabolic Pathways probe set. Genes with
counts under 100 were eliminated from analysis. Coloring indicates relative expression of each
gene, from low (blue) to high (red). Heatmap generated on Morpheus.
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CHAPTER 4: FUTURE DIRECTIONS AND CONCLUDING REMARKS
4.1. Overall summary of data and significance
The metabolic pathways that synthesize and break down nutrients are a critical
facet of cellular survival, homeostasis, proliferation, and function. In all cells, particularly
immune cells, bioenergetic needs are dynamic and contextual, varying across
differentiation and functional states as well as the extracellular environment. In TCONV,
naïve, effector, and memory differentiation states are tightly associated with distinct
metabolic programs that support different functions during different activation states.
Whereas naïve T cells and memory T cells tend to rely predominantly on oxidative
metabolic programs (OXPHOS and FAO), upon differentiation into effector T cells,
metabolic reprogramming occurs that enables a shift to increase glucose and glutamine
metabolism. These anabolic metabolic pathways provide effector TCONV the nutrients
required for cell growth, proliferation, cytokine production, and cytotoxicity. While
glycolysis allows for short-term effector functions of TCONV, memory T cells that mainly
utilize FAO tend to be longer-lived effector cells, which is particularly important within the
context of adapting to the harsh, nutrient-poor solid tumor microenvironment (TME), as
discussed in Chapter 2. It is now well-appreciated that immunometabolism is linked to
long-term persistence within the TME, and thus this research area is a very
translationally relevant one that is deserving of more thorough exploration.
While the link between cellular metabolism and effector functions is fairly wellunderstood in TCONV, conversely, very little is known about invariant natural killer T
(iNKT) cell immunometabolism to date. As described in Chapter 1, iNKT cells constitute
a rare subset of T cells that possess specificity for glycolipid antigens presented by the
monomorphic CD1d molecule. Interestingly, iNKT cells also possess NK-like features
and are pre-primed for activation. Although iNKT cell frequencies in both human and
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murine peripheral organs are relatively rare, iNKT cells play very important roles in antitumor immunity and indeed, their frequencies in peripheral blood and within tumors
correlate with improved prognosis and survival in many different tumor types. iNKT cells
can engage both direct cytotoxicity of CD1d-expressing tumor targets as well as by
enhancing the anti-tumor activity of many other immune effector cell populations and by
inhibiting suppressive immune populations. Despite these potent anti-tumor properties,
iNKT cell-based immunotherapies remain in very early clinical stages. Although iNKT
cell-based adoptive therapies have been demonstrated to be well-tolerated and safe,
unlike TCONV, we have very little knowledge about their persistence within the tumor
microenvironment (TME) of solid tumors. The harsh, nutrient-poor immunosuppressive
TME imposes metabolic challenges to the survival and prolonged effector functions of
TCONV long-term that impedes the success of T-cell based immunotherapies. Therefore, it
is critical to better understand the metabolic features that govern the ability of iNKT cells
to adapt to the TME and survive and maintain anti-tumor functions long-term. This
knowledge would not only better inform how to more effectively harness the anti-tumor
activity of iNKT cells for therapeutic benefit, but also provide insight into the clinical
scalability of expanding these cells to infuse into patients, which will be discussed later in
this chapter.
In Chapter 3, we present our findings that demonstrate novel differences in
metabolic properties of human PBMC-derived iNKT cells relative to TCONV. Notably, we
find that upon stimulation, iNKT cells are less reliant on glucose and glutamine for
effector functions, evident by their ability to retain both IFN-g production and intracellular
granzyme B levels in glucose-deplete and glutamine-deplete culture conditions in vitro,
whereas TCONV effector functions were abrogated in each of these conditions.
Furthermore, we performed NanoString transcriptional analysis of metabolic pathway
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genes, and find that stimulated iNKT cells appear to be less glycolytic than TCONV,
expressing lower levels of glycolysis enzyme genes and Myc signaling genes relative to
stimulated TCONV. In addition to these differences in glucose and glutamine metabolism
between these cells, we also find that both rested and stimulated iNKT cells express
higher levels of FAO genes, and indeed, stimulated iNKT cells have higher intracellular
levels of Cpt1a, the rate-limiting enzyme of FAO. Finally, we performed Seahorse flux
analysis which revealed that although stimulated iNKT cells are overall less
metabolically active than stimulated TCONV, they tend to rely on fatty acids as a substrate
for oxidation more so than TCONV, constituting an important metabolic difference between
these two cell types. Intriguingly, however, iNKT cells do not appear to depend upon
FAO or extracellular lipids for their effector functions, as when these pathways are
inhibited, they still retain cytokine production and cytotoxicity. This data could together
imply that iNKT cells may be metabolically flexible in that they can switch metabolic
pathways when a singular pathway is inhibited or nutrients are unavailable; alternatively,
it is also possible that iNKT cells utilize alternate metabolic mechanisms by which to
retain effector functions upon nutrient depletion, such as autophagy. While further
studies will be needed to address these particular questions, we importantly described
for the first time that human iNKT cells possess a unique metabolic profile from TCONV,
with differential bioenergetic requirements for anti-tumor functions. These distinct
metabolic requirements could have important implications for the ability of these cells to
survive and retain function within the solid tumor TME.
Although these discoveries are important to our understanding of
immunometabolism, there are many future studies that would not only address some of
the limitations of this work, but also further enhance our understanding of how to
harness the immunometabolic features of these cells for therapeutic benefit. Some of
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these next steps and approaches for answering remaining questions are discussed
further in the section below and summarized in Figure 4.1.

4.2. Remaining questions and future directions and approaches
Profiling heterogeneous iNKT cell subsets
For all of our iNKT cell immunometabolism studies in Chapter 3, we sorted
expanded PBMC-derived iNKT cells, defined by a Vα24+CD3+ phenotype. Though our
findings revealed intriguing differences in the bioenergetic requirements of rested and
stimulated iNKT cells relative to TCONV, one limitation of our work is that we profile a bulk
iNKT cell population. It is well-appreciated that both mouse and human iNKT cells
possess phenotypic and functional heterogeneity. As discussed in Chapter 1, NKT cells
can be classified into different subsets based on the pro-and anti-inflammatory cytokines
they secrete, including NKT1 (Th1-like), NKT2 (Th2-like), NKT17 (Th17-like), and Treglike NKT cells (Brennan et al., 2013). These subsets are well-defined in mouse NKT
cells, and although these subsets apply to human iNKT cells as well (Lee et al., 2002),
the exact frequencies and functional properties of human iNKT cells within peripheral
blood iNKT cells is not fully understood. Interestingly, a recent single-cell RNAsequencing study of bulk human PBMCs found several unique “clusters” of both
unstimulated and stimulated iNKT cells within peripheral blood that each possessed
distinct transcriptional profiles (Zhou et al., 2020). Within the stimulated iNKT cells, the
subsets differed in expression of cytokines, chemokines, co-stimulatory pathways, and
additional signaling pathways involved in basic cellular functions and interactions with
other immune populations. Given these functional differences, these subsets may also
display unique metabolic properties. Together, this suggests that the PBMC-derived
iNKT cells we expand for our studies likely have mixed metabolic and functional
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properties that should be dissected further for a more nuanced understanding of iNKT
cell immunometabolism.
To preliminarily identify the functional subsets within our expanded iNKT cells,
we recently profiled the cytokine profiles of bulk expanded PBMCs from four
independent healthy human donors utilized in many of the studies in Chapter 3.
Specifically, we stained for intracellular Foxp3, Gata3, and T-bet, and observed that
while the majority of iNKT cells express high levels of T-bet (indicative of a Th1
phenotype, which we would expect with α-GalCer stimulation), interestingly, there was a
substantial proportion of these cells also positive for Foxp3 and Gata3 – though these
frequencies varied in each donor from approximately 15%-50% for Foxp3+ and 20-90%
for Gata3+ (Figure 4.2A). Although it is not entirely clear why some of these cells may
be expressing multiple cytokines, our preliminary flow data suggests that our expanded
iNKT cell population that we rested and stimulated in our studies may possess mixed
cytokine secretion profiles. Furthermore, from our MSD cytokine analysis in glucose and
glucose-depleted iNKT cells and TCONV (Chapter 3, Figures 3.5 and 3.12), we also
observed that these purified iNKT cells produce substantial levels of IFN-g, TNF-α, IL-2,
and IL-4, further supporting the notion that these iNKT cells constitute a functionally
diverse population. This in turn could mean that the underlying metabolic properties of
these functional subsets of iNKT cells may also be variable.
In addition to diverse cytokine secretion subsets, iNKT cells also display
variability in their phenotypic expression of CD4 and CD8. Murine NKT cells may be
CD4+ or DN, and human NKT cells can be CD4+, DN, or CD8+ (Godfrey et al., 2010).
While these phenotypic features are not completely akin to CD4+ and CD8+ TCONV
functionally, there is some evidence that these phenotypic subsets may have unique
properties; for example, DN iNKT cells have been shown to be more cytolytic and
115

express higher surface expression of NK cell receptors than CD4+ iNKT cells (Cohen et
al., 2013). Though these phenotypic subsets have not been extensively characterized in
human PBMC-derived iNKT cells, it is possible that our population contains a mix of
these iNKT cells that may be influencing our bulk metabolic and functional data. Indeed,
our preliminary flow analysis of expanded iNKT cells in four human donors found that
while CD8+ iNKT cells were consistently very rare (>5% of total iNKT cells), the
distribution of CD4+ and DN iNKT cells in three out of four donors was ~7-20% CD4+ and
~58-70% DN; however, this was also variable, as one donor had a greater percentage of
CD4+ iNKT cells (52%) than DN iNKT cells (22%) (Figure 4.2B). Thus, it would be useful
in future studies to sort these different iNKT cells and examine their immunometabolic
features individually, as there may be variability in these different subsets as well.
One of the major limitations we faced in investigating iNKT cell
immunometabolism was the large cell numbers required for metabolic assays. For this
reason, we expanded PBMCs and opted to rest and stimulate them after expansion in
order to have a sizeable population to work with, particularly for assays such as
Seahorse Flux Analysis that require several million cells to obtain reliable data. To
circumvent this limitation of Seahorse assays, a new technique was recently designed
that allows for profiling of the metabolic activity of small numbers of cells at single-cell
resolution by using flow cytometry. This method is called single-cell energetic
metabolism by profiling translation inhibition, or SCENITH (Argüello et al., 2020). The
principle of SCENITH is that protein synthesis can be used as a surrogate measure for
global metabolic activity, in that half of the total energy produced by mammalian cells
from the breakdown of glucose, amino acids, and lipids is used for this metabolic
process. As such, the use of puromycin – a drug that inhibits protein synthesis in cells
and can serve as a reliable readout for measuring protein synthesis levels in vitro and in
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vivo – can, in turn, be used as a readout for metabolic activity. The authors developed a
novel monoclonal antibody directed towards puromycin that allows for the measure of
cellular metabolic activity and dependencies on specific pathways (like glycolysis, FAO,
and OXPHOS) by quantifying levels of puromycin staining upon treatment with various
metabolic inhibitors that are used in Seahorse assays (Figure 4.3). Indeed, in comparing
SCENITH side-by-side with Seahorse flux in steady-state and activated T cells, the
findings were consistent (Argüello et al., 2020) and thus suggest that SCENITH can be
an effective method by which to study cellular metabolism. Importantly, this will
revolutionize the field of immunometabolism and allow the ability to not only characterize
metabolic profiles of very small subsets of cells on a single-cell level, but also correlate
this metabolism with other functional markers by flow. Importantly, this can be used to
study rare subsets of iNKT cells (and other immune cells) within both peripheral blood
and in tumor samples, which currently is very difficult using Seahorse assays.
In addition to SCENITH, another recently published method by which to study
metabolism by flow cytometry is Met-Flow (Ahl et al., 2020). Unlike SCENITH, Met-Flow
does not serve as a surrogate for metabolic pathway activity and dependency, but rather
identifies a panel of antibodies targeting rate-limiting enzymes in several key metabolic
pathways that can be stained intracellularly to allow characterization of underlying
cellular metabolism. Specifically, the flow panel includes antibodies targeting: SLC20A1
(phosphate transporter), ASS1 (arginine biosynthesis), SLC2A1/Glut1 (glucose uptake),
IDH2 (TCA cycle), G6PD (pentose phosphate pathway), ACAC/ACC1 (fatty acid
synthesis), PRDX2 (antioxidant metabolism), HK1 (glycolysis), CPT1A (fatty acid
oxidation), and ATP5F1A (ATP biosynthesis). Because this method is flow-based, it
allows for the direct correlation of metabolic and functional properties within small
populations of cells by co-staining for phenotypic and functional activation markers.
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Another advantage of Met-Flow is that it is a relatively feasible assay to run, as the
metabolic antibodies are all commercially available.
The use of SCENITH and Met-Flow would provide the ability to effectively profile
heterogenous iNKT cell populations. For example, we could profile unstimulated iNKT
cells directly from peripheral blood (without the need for expansion in culture), as well as
individual phenotypic subsets of iNKT cells (CD4+, DN, and CD8+), and finally, different
cytokine-secreting subsets of iNKT cells (i.e. NKT1, NKT2, NKT17, Treg-like NKT cells).
The metabolic profiles of these iNKT cell subsets could also be correlated to different
subsets of TCONV as well, to more thoroughly examine which populations of iNKT cells
are most similar or different from TCONV. Together, this data would allow for a much more
comprehensive correlation between metabolic profiles and effector functions of iNKT cell
subtypes. Importantly, in addition to the mechanistic inputs these data would provide, it
also would be a critical next step for better identifying which iNKT cell sub-populations
may be most suitable for clinical use with regard to both ex vivo expansion and ability to
persist within the TME.

Investigating the immunometabolism of intratumoral iNKT cells
An important next step for understanding how the immunometabolism of iNKT
cells directly influences their anti-tumor activity will be to metabolically profile iNKT cells
from within solid tumors. Based on the differences we observe in iNKT cell effector
function sensitivity relative to TCONV when placed in TME-like conditions in vitro (glucoseand glutamine-deplete culture), we would hypothesize that these immunometabolic
features are also similar within the TME. However, we ultimately have only profiled
peripheral blood-derived iNKT cells, and it is certainly possible that their metabolism
varies by peripheral tissues, particularly within the TME, where they face nutrient
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competition with tumor cells, stromal cells, and immunosuppressive cells. Ideally, the
best way to truly compare iNKT immunometabolic features and understand its
translational relevance would be to profile human patient tumor samples. A more
feasible alternative approach is the utilization of mouse solid tumor models. This
approach, combined with novel metabolic techniques like SCENITH and Met-Flow,
would enable us to investigate the immunometabolic features of intratumoral iNKT cells
in the future.
Our lab has begun to delineate the properties of immune effector cells, including
iNKT cells, within the TME, using a solid tumor murine model recapitulating human
disease. Specifically, through a collaboration with Dr. Michael Hogarty, we have
performed studies on a murine model of high-risk neuroblastoma (NB), a pediatric
embryonal solid malignancy; the high-risk form of NB, driven by amplification of the
MYCN oncogene, is particularly aggressive and has a relatively high mortality rate
(Maris et al., 2007). The TH-MYCN+/+ transgenic mouse model is comprised of a MYCN
gene under the control of the tyrosine hydroxylase promoter, thereby conferring
autochthonous tumor growth in the adrenal glands and sympathetic ganglia of mice
(Weiss et al., 1997). Importantly, this makes for an excellent in vivo model by which to
probe the properties of immune effector cells within the TME, as it is not only
immunocompetent, but recapitulates human high-risk NB genetically and histologically
(Hackett et al., 2003; Teitz et al., 2011). In this model, tumors uniformly form at
approximately 21 days of age, and tumor-bearing mice die at approximately 40-50 days
of age. Because NB tumors do not possess staging, we immunophenotyped terminalstage tumors to identify the relative frequencies of different immune populations present
in these tumors.
Interestingly, our immunophenotyping analyses revealed that NB tumors possess
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a higher frequency of iNKT cells relative to conventional CD4+ and CD8+ T cells (Figure
4.4). Though there was some variability across tumors, the frequencies of iNKT cells in
NB tumors ranged from ~2-8%; notably, this is significantly higher than the levels found
in peripheral blood and most organs. Furthermore, in human NB patients, the presence
of intratumoral iNKT cells predicts better five-year survival and tumor prognosis
(Metelitsa et al., 2004; Hishiki et al., 2018), indicating that they have an important role in
anti-tumor immunity of NB. Although iNKT cells are found at high frequencies in
terminal-stage tumors (as well as in newly formed, day 21 TH-MYCN+/+ tumors; data not
shown), we do not know if they are actually activated within these tumors. Though we
have preliminarily observed that these intratumoral iNKT cells express some level of
intracellular IFN-g, this may be from moderate stimulation via CD1d-expressing
hematopoietic cells within the NB TME and/or from cytokines secreted within the TME.
However, these cells are likely not at their full activation potential, as neuroblasts do not
express CD1d. Therefore, we sought to develop a way by which we can directly
stimulate iNKT cell anti-tumor activity in situ within these tumors, not only for therapeutic
benefit, but also as a useful tool by which to study the properties of stimulated iNKT cells
within a TME. To do so, our lab developed conjugate CD1d-mAb molecules (termed
“CAbs”) comprised of stimulatory glycolipid antigen-loaded CD1d molecules
biochemically fused to antibodies targeting GD2, a disialoganglioside that is highly
expressed on NB tumors (Figure 4.5). Proof-of-concept studies demonstrated that these
GD2-CAb molecules could effectively induce iNKT cell killing of GD2-expressing target
cells in vitro (data not shown). Subsequently, we found that upon acute injection of
loaded GD2-CAb constructs into tumor-bearing TH-MYCN+/+ mice, intratumoral iNKT
cells displayed significant induction of the surface activation marker CD69, CD107a
expression (a degranulation marker), and intracellular IFN-g relative to injection of
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controls (saline or glycolipid antigen alone) (Figure 4.6). Importantly, corresponding liver
iNKT cells from these mice did not have any induction of activation or functional markers
relative to controls, and NK cells and TCONV from both livers and tumors also did not show
any significant change in these markers across the different treatment groups. Thus,
these data indicate that treatment with GD2-CAb serves as an effective tool by which to
specifically, directly redirect intratumoral iNKT cell activation in NB tumors. This CAb
construct could also be modulated to target any tumor-specific antigens, enabling its
utility for a variety of solid tumor models. To investigate the immunometabolism of
intratumoral iNKT cells, one could treat these tumor-bearing mice with GD2-CAb or
controls and compare the metabolic properties of “baseline” and “stimulated” iNKT cells
within the TME using flow-based methods like Met-Flow to co-stain metabolic enzymes
with functional markers such as IFN-g and granzyme B. Alternatively, these populations
could also be FACS-sorted from tumors and transcriptionally profiled – for example,
using the NanoString Metabolic Pathways probe set used in Chapter 3 – to provide a
more detailed characterization of iNKT cell metabolic and functional properties within the
TME. These would both be important studies to better understand the potential
translational significance of iNKT immunometabolism.

Linking immunometabolism to the design of more effective cellular immunotherapies
The advances in the field of immunometabolism have enhanced our
understanding of the fundamental metabolic properties enabling immune cell
homeostasis, survival, proliferation, and response to stimuli. Importantly, from a
translational standpoint, the metabolic features of immune effector cells including T cells
have been shown to have critical implications for their ability to expand ex vivo and
persist long-term within solid tumors. For solid tumors, a major challenge for the efficacy
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of cellular immunotherapies has been the ability of immune cells to out-compete tumor
cells for limited nutrients in order to persist and maintain function long-term in the TME
for a durable response. As such, immunometabolism has become a key component to
developing more effective cellular immunotherapies. Our novel findings on iNKT cell
metabolic properties and bioenergetic demands could have important therapeutic
significance that could be explored further to co-opt for the design of iNKT cell-based
anti-tumor therapies.
One of the major focuses in improving the efficacy of T cell-based
immunotherapy platforms is to identify the best populations of T cells to expand in
culture that will enable prolonged and durable responses in a broader range of patients.
Several studies have demonstrated that T cells with more central, stem-like memory
properties demonstrate higher anti-tumor immunity potential (Gattinoni et al., 2011;
Hinrichs et al., 2009; Klebanoff et al., 2011; Kishton et al., 2017). These properties can
be modulated both through tailored design of the cell therapy products themselves, or in
the expansion of these cells prior to patient infusion (Rangel Rivera et al., 2021).
With regard to modulating cell therapy products directly, the co-stimulatory
domains of CAR-T cells have been shown to directly influence their metabolism and in
vivo efficacy. Indeed, the June lab discovered that CAR-T cells transduced with CD28
co-stimulatory domains were highly glycolytic and displayed a terminally differentiated
phenotype with less persistence, whereas 4-1BB-transduced CAR-T cells displayed
higher PGC1-α (mitochondrial biogenesis) and oxidative metabolism, as well as better
persistence (Kawalekar et al., 2016). Notably, though these findings were in vitro, they
support clinical observations from early trials demonstrating that CD28-CARs had higher
incidences of cytokine release syndrome and persistence lasting for a duration of
months (Davila et al., 2014), whereas 4-1BB-CARs persisted for years and exhibited
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lower T cell exhaustion (Porter et al., 2015; Long et al., 2015). Interestingly, these data
are also aligned with observations in iNKT cells that 4-1BB-transduced iNKT cell CARs
demonstrated greater persistence as well (in vitro and in animal models) (Heczey et al.,
2014), discussed in Chapter 1; whether this is linked to metabolism in iNKT cells is still
unknown, but could be an important aspect underlying the functional features of these
CAR products in iNKT cells as well.
In addition to engineering these cells directly to be more metabolically fit, it is
also clear that the expansion of T cells influences their ability to persist and provide
prolonged responses in patients. Indeed, mitochondrial metabolism and FAO promote
stem-like properties that confer TCONV enhanced proliferative capacity, longevity, and
recall ability, together promoting better anti-tumor immunity and rendering these T cells
more “fit” (Sukumar et al., 2016). Interestingly, it has been shown that culturing T cells in
nutrient-deprived stress conditions can actually more effectively delay tumor growth in
vivo, presumably because they are better metabolically adapted to these conditions and
finding alternative fuel sources (Eil et al., 2016; Sukumar et al., 2013). For instance, T
cells cultured with low glucose had greater stem and central-memory properties,
reduced terminal differentiation, and more effectively exerted effector functions in mouse
tumors – these functional features were all associated with increased usage of
mitochondrial respiration and FAO metabolism (Sukumar et al., 2013). In addition, the
cytokines that these cells are cultured with in vitro may play an important role in
determining their persistence and proliferative capacity. For instance, IL-15 improves
mitochondrial fitness and anti-tumor immunity (van der Windt et al., 2012), and IL-21
prevents T cell terminal differentiation as well (Hinrichs et al., 2008). Collectively, it is
thus evident that the ex vivo expansion properties of TCONV – which are tightly linked to
metabolism – play a direct role in the efficacy of these cells in anti-tumor immunity and
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represent an important area of further investigation for developing more effective cellular
immunotherapies moving forward.
In contrast to T cell-based immunotherapies, the use iNKT cell-based
immunotherapies remains limited thus far, as these are still in early clinical stages
(discussed more extensively in Chapter 1, section 1.4). Although the clinical trials to date
have revealed that iNKT cells are safe and well-tolerated by patients, two of the major
challenges within this field are (1) the expansion potential of iNKT cells, and (2) lack of
knowledge of iNKT cell persistence within the TME. Given the importance of metabolism
in governing these properties in TCONV, it will be essential to enhance our understanding
of iNKT cell metabolic properties in order to inform the design these therapies in iNKT
cells in the future.
With regard to iNKT cell numbers, because these cells are relatively rare, it is
critical to develop optimal ways to expand these cells in culture in order to enrich for the
sub-populations that will be most therapeutically effective and obtain sufficient quantities
to infuse into patients. Recently, Zhu et al. demonstrated the preclinical feasibility and
efficacy of hematopoietic stem cell (HSC)-derived human iNKT cells to effectively traffic
to tumors and induce anti-tumor cytotoxicity in both hematologic and solid tumor human
xenograft murine models (Zhu et al., 2019). If this could be recapitulated in human
cancer patients, it may allow for greater scalability and broader utility of iNKT-cell based
immunotherapies. Importantly, the immunometabolic properties of iNKT cells could help
identify the best populations to expand in vitro that are most likely to have greater in vivo
persistence for adoptive therapy approaches or for transduction of CAR-iNKT cells.
Indeed, if we were able to effectively subset iNKT cells to identify at a more granular
level which of these cells were more memory-like in metabolism – i.e. identify those with
high Cpt1a, high mitochondrial mass, and resistance to glucose and glutamine inhibition
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– we could focus on expanding these cells for clinical use. In support of this notion, two
studies of both ex vivo-expanded iNKT cells and CAR-iNKT cells have demonstrated
that the most persistent effector populations that retain anti-tumor function and maintain
longevity within the TME are those that express CD62L (Tian et al., 2016) and are
transduced with IL-15 (Xu et al., 2019). Notably, in TCONV, IL-15 promotes a more
memory-like metabolic profile (van der Windt et al., 2012), and CD62L is also a central
memory marker that is correlated with stem-like properties and enhanced anti-tumor
efficacy (Graef et al., 2014; Sommermeyer et al., 2016; Wang et al., 2012). In addition to
IL-15, interestingly, IL-21 was also shown to promote the enrichment of these central
memory-like CD62L+ iNKT cells; indeed, IL-21-expanded CAR-iNKT cells demonstrate
greater anti-tumor efficacy in vivo (Ngai et al., 2018). Together, these data further
support that there is likely a critical link between the expansion of iNKT cells and
underlying metabolism and persistence within tumors. Ultimately, the metabolic and
functional profiling of subsets of iNKT cells both in expanded PBMCs and intratumorally
will inform the use of these cells for therapeutic purposes and constitute a very important
next direction in advancing both our knowledge of immunometabolism and the design of
solid tumor immunotherapies.

4.3. Concluding Remarks
Over the past several years, there has been a growing interest in harnessing the activity
of immune cells for developing novel disease therapies. Anti-tumor immune cells are key
contributors to mediating tumor regression in many tumor types, and as such, the use of
immunotherapies has revolutionized cancer care. Unfortunately, only a small subset of
patients has benefited from the potential of immunotherapies; in particular, many solid
tumors remain very difficult to treat, and many patients do not respond to existing cellular
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therapies. To design better immunotherapies for solid tumors, it is critical that we gain a
better understanding of how to: best harness the activity of different immune populations
to engage anti-tumor cytotoxicity, best expand these immune cells, and determine how
these cells can adapt to and persist within the tumor microenvironment (TME) to exert
long-term tumor regression. Though the TME imposes many challenges for the success
of T cell-based immunotherapies, the use of iNKT cells may be appealing, as these cells
display potent and multimodal anti-tumor mechanisms and are relatively well-tolerated
by patients. However, our knowledge of the fundamental cellular properties of iNKT
cells, including their cellular metabolism – which may govern their ability to adapt to the
TME – is still quite limited. This thesis work importantly, for the first time, characterizes
the immunometabolic properties of both resting and stimulated human primary iNKT
cells relative to TCONV. Our work identifies key differences in the bioenergetic
requirements of these two cell types, and implies that iNKT cells – which have a more
memory-like profile and the ability to retain effector functions in nutrient-deplete
conditions – could potentially be better suited to the harsh, nutrient-poor conditions of
the TME. Further studies investigating the immunometabolism of individual subsets of
iNKT cells both in vitro and within tumors will be essential next steps for translating these
discoveries into designing more effective iNKT-cell based immunotherapies. The
growing appreciation for how metabolism can influence immune cell function and their
responses to tumors has greatly advanced the field of immunometabolism over the past
few years in particular, and more sophisticated methods for probing metabolic features
are being developed. Thus in the future, it will be exciting to investigate
immunometabolism on a single cell level and discover more pathways and mechanisms
different immune cell populations can exert to engage anti-tumor activity. These findings
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will not only greatly advance our understanding of basic cellular immunology, but also
greatly impact the treatment of patients of many immune-mediated diseases.
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4.4. Figures

Figure 4.1: Overview of iNKT cell metabolism future directions.
Diagram created using BioRender.
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Figure 4.2: Expanded PBMC-derived iNKT cells are phenotypically and functionally
diverse. Bulk PBMCs were expanded for iNKT cells as addressed in the methods section in
Chapter 3.4. On day 7 of expansion, cells were stained for flow cytometry of surface markers and
intracellularly stained using the Transcription Factor intracellular kit per manufacturer’s protocol.
Cells were first gated on live, singlets, followed by Va24+CD3+ cells (iNKT cells). iNKT cells were
then analyzed for the indicated (A) transcription factors (relative to isotype controls), and (B)
surface CD4 and CD8 expression (relative to unstained controls). Samples were run on an LSR II
cytometer (housed at the CHOP Flow Cytometry Core). Each colored dot represents individual
donor replicate (n=4 total). Analysis was performed using FlowJo software and graphs generated
in GraphPad Prism by Nicole Zaragoza-Rodriguez.
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Figure 4.3: Overview of SCENITH metabolic measures and advantages.
Taken from Arguello et al., Cell Metabolism (2020).
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Figure 4.4: Immune compartment of TH-MYCN+/+ neuroblastoma tumors contain
significantly higher iNKT cells and NK cells relative to conventional CD4+ and CD8+ T cells.
Tumors were harvested from tumor-bearing mice at terminal stage and dissociated using
collagenase IV and DNase in a GentleMACS machine. Dissociated mononuclear cells were
stained with antibodies against CD45, CD3, CD4, CD8, NK.1.1, and CD1d tetramers. Graph
indicates percentages of each immune cell type in live, singlet, CD45+ gate. Each dot represents
individual tumor sample. Samples were run on a BD FACSVerse flow cytometer and analyzed
using FlowJo software. Data generated with Adriana Benavides.
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Figure 4.5: Schematic of CAb molecule.
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Figure 4.6: iNKT cells in TH-MYCN+/+ NB tumors can be acutely activated by GD2-CAb
molecule. Tumor-bearing mice (day 31-40) were injected intraperitoneally with 8ug GD2-CAb,
4ug PBS44 (glycolipid antigen (GAg) alone)), or PBS. After 4 hours, mice were sacrificed and
tumors were dissociated. Livers were also harvested and processed. All samples were stained for
flow cytometry for phenotypic markers (CD3, CD4, CD8, CD1d tetramer, NKp46) and functional
markers as indicated, using the BD Cytofix/Cytoperm kit. iNKT cells were gated as CD3+, CD1d
tetramer+ (intracellular) cells and profiled for (A) CD69 (surface activation marker), (B)
intracellular IFNg, and (C) surface CD107a (degranulation marker). All samples were run on an
LSR II cytometer. Data was analyzed with FlowJo software and mean fluorescent intensity (MFI)
for indicated markers was quantified for each immune population tested (iNKT cells, NK cells, T
cells). One-way ANOVA was performed for each treatment group - asterisks indicates statistical
significance (*p < 0.05; *** p < 0.001). Data generated with Gabrielle Ferry.
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